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ARTICLE
The oncogene AAMDC links PI3K-AKT-mTOR
signaling with metabolic reprograming in estrogen
receptor-positive breast cancer
Emily Golden1,2,27, Rabab Rashwan1,2,3,27, Eleanor A. Woodward1,2,27, Agustin Sgro1,2,4, Edina Wang1,2,
Anabel Sorolla 1,2, Charlene Waryah1,2, Wan Jun Tie1,2, Elisabet Cuyàs1,5,6, Magdalena Ratajska 7,8,9,
Iwona Kardaś7,10, Piotr Kozlowski 11, Elizabeth K. M. Johnstone 2,12,13, Heng B. See2,12,13, Ciara Duffy1,2,4,
Jeremy Parry14, Kim A. Lagerborg 15, Piotr Czapiewski16,17, Javier A. Menendez5,6, Adam Gorczyński16,
Bartosz Wasag 7,10, Kevin D. G. Pfleger2,12,13,18, Christina Curtis 19, Bum-Kyu Lee20, Jonghwan Kim 21,
Joseph Cursons 22, Nathan J. Pavlos8,23, Wojciech Biernat 16, Mohit Jain15, Andrew J. Woo 2,24,
Andrew Redfern25 & Pilar Blancafort 1,2,4,26✉
Adipogenesis associated Mth938 domain containing (AAMDC) represents an uncharacterized
oncogene amplified in aggressive estrogen receptor-positive breast cancers. We uncover that
AAMDC regulates the expression of several metabolic enzymes involved in the one-carbon
folate and methionine cycles, and lipid metabolism. We show that AAMDC controls PI3K-
AKT-mTOR signaling, regulating the translation of ATF4 and MYC and modulating the
transcriptional activity of AAMDC-dependent promoters. High AAMDC expression is asso-
ciated with sensitization to dactolisib and everolimus, and these PI3K-mTOR inhibitors exhibit
synergistic interactions with anti-estrogens in IntClust2 models. Ectopic AAMDC expression
is sufficient to activate AKT signaling, resulting in estrogen-independent tumor growth. Thus,
AAMDC-overexpressing tumors may be sensitive to PI3K-mTORC1 blockers in combination
with anti-estrogens. Lastly, we provide evidence that AAMDC can interact with the
RabGTPase-activating protein RabGAP1L, and that AAMDC, RabGAP1L, and Rab7a colocalize
in endolysosomes. The discovery of the RabGAP1L-AAMDC assembly platform provides
insights for the design of selective blockers to target malignancies having the AAMDC
amplification.
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Analysis of transcriptomic data has traditionally stratifiedbreast cancers (BCs) into six subtypes: hormone receptor-positive (HR+) luminal A and luminal B, HER2-enriched
(HER2+), basal-like, claudin-low, and normal-like1,2. While
luminal A tumors generally respond well to anti-hormonal
therapies, luminal B tumors often lose HR-driven transcriptional
programs and have higher rates of mortality3. To date, there are
no clinical biomarkers to stratify the fraction of HR+ tumors with
a high probability of relapse from the bulk of malignancies that
respond to traditional anti-hormonal approaches3. Current
diagnostic tests, such as Oncotype Dx, are limited to the deter-
mination of whether the addition of cytotoxic chemotherapy can
provide a therapeutic benefit, rather than identifying rational
drug targets to directly inhibit oncogenic drivers4.
More recent studies integrating both transcriptomic and
genomic datasets have provided further insights into breast
cancer heterogeneity by defining 10 different integrative clusters
(IntClust) subtypes. A subgroup of estrogen receptor-positive (ER
+) cancers (IntClust2) has been identified with a prognosis
inferior to all but the HER2-enriched group (IntClust5). The
hallmark of IntClust2 tumors is focal amplification of a region of
chromosome 11 (chr 11) (11q13.5–14.1) defining a cis-acting
oncogenic cluster5. This subtype harbors genomic and tran-
scriptional alterations in cell cycle-related genes, including the
MYC targets CCND1 and CCNE1, and displays aggressive beha-
vior including a high level of proliferation and endocrine therapy
resistance5. The 11q13.5–14.1 amplicon encompasses 12 potential
oncogenes, two with recognized roles in anti-estrogen and
paclitaxel resistance in breast and ovarian cancer: RSF16 and
PAK17, and at least three targets in the amplicon are known to
regulate metabolic processes: NDUFC28, ALG89, and THRSP10.
Importantly, AAMDC (Adipogenesis associated Mth938 domain
containing), is centered in the peak of the amplicon, and it thus
represents one of the most frequently amplified genes in the
cluster, highlighting a prospective biomarker for IntClust2 subtype
identification as well as a potential pathogenic driver for these
cancers.
AAMDC encodes a 122 amino acid protein of unknown
function that has a high degree of structural homology with a
bacterial protein from M. thermoautotrophicum, thus suggest-
ing collateral gene transfer from bacteria to eukaryotic cells11.
The induction of adipogenesis upon overexpression of the
murine homolog of AAMDC in 3T3-L1 pre-adipocyte cells12,
together with its observed pattern of mRNA expression in
white adipose tissue, suggests a potential role for this gene in
metabolism. However, the distribution and function of this
putative protein in human cancers has not been previously
investigated.
Our results indicate that AAMDC is a signal transduction
oncoprotein that constitutively activates the PI3K-AKT-
mTOR pathway, thereby inducing survival of ER+ BCs dur-
ing metabolic stress conditions such as estrogen deprivation.
Our work suggests that the proliferation and survival of
IntClust2 malignancies may be dependent on metabolic
reprograming, and hence these poor prognosis ER+ tumors
could be vulnerable to tailored therapies focusing on PI3K-
mTOR inhibitors in combination with anti-estrogens. The
discovery of potential binding interfaces between AAMDC
and RabGAP1L (Rab-GTPase activating protein) could assist
in the development of inhibitors to target these currently
hard-to-drug proteins. We propose that the identification of
AAMDC-overexpressing tumors could facilitate the identifi-
cation of patients with a poor prognosis and the development
of selective therapeutic interventions against this aggressive
subtype of ER+ disease.
Results
Overexpression and amplification of AAMDC in ER+ BCs.
Examination of oncogenomic databases revealed frequent
AAMDC copy number alterations in a broad array of patient
samples, including breast, ovarian, lung, and prostate cancers
(Fig. 1a). These were predominantly amplification alterations,
with infrequent gene mutation or deletion events, and a frequency
of amplification of ~10% of BC cases across multiple databases
(Fig. 1a). Tumors with high AAMDC expression had inferior
overall survival in breast, ovarian, and lung cancers. In addition,
high expression of AAMDC significantly correlated with lower
survival in aggressive luminal B BCs treated with tamoxifen, thus
suggesting an association with anti-estrogen therapy resistance
(Fig. 1b).
To explore the demographics of AAMDC expression, we
performed immunohistochemistry (IHC, Fig. 1c) in a breast
tissue microarray (Biomax) including normal breast tissue,
benign breast lesions, and 60 high-risk BC cases (Supplementary
Fig. 1a and b for validation of the α-AAMDC antibody).
AAMDC, as quantified by the H-index (intensity × % positive
cells), was basally expressed at lower levels in normal and non-
luminal cells and at higher levels in in situ carcinoma. As
expected from genomic databases, the antigen was selectively and
significantly overexpressed in ER+ relative to ER− breast tumors
(47 vs. 15%, χ2 p= 0.005; Supplementary Table 1). AAMDC+
cancers exhibited the highest expression in the cytoplasm, with
relatively frequent but a lower level of nuclear and membrane-
associated staining (Fig. 1c). Even within this high-risk patient
series, tumors with a high level of nuclear expression showed
more frequent lymph node involvement (48 vs. 24%, p= 0.03)
and an increase in the proportion of tumors >5 cm (36 vs. 14%,
p= 0.03). Interestingly, in contrast to the nuclear staining, these
correlations were not significant for the cytoplasmic staining
(Fig. 1d, Supplementary Table 1).
To validate the frequency of AAMDC amplification in high-
risk HR+ BCs, fluorescence in situ hybridization (FISH) was
conducted on a focused cohort of 119 luminal B BCs using probes
for AAMDC and Centromere enumeration 11 (CEN-11). Notably,
25% of the luminal B tumors screened exhibited AAMDC
amplification, with amplification indexes from >2–5, and a
further 11% displayed a chr 11 polysomy, with a trend of the
amplification correlating with lymph node involvement (Fig. 1e,
Supplementary Data 1). Although AAMDC expression and
amplification did not correlate with HER2 positivity, they were
not mutually exclusive to this such that both amplifications could
exist within a single tumor (Supplementary Table 1 and
Supplementary Data 1).
Consistent with the clinical data, the overexpression and
amplification of AAMDC were predominant in ER+ luminal cell
lines, with the highest level of expression in MDA-MB-134,
SUM52PE, and SUM44PE, all of which harbored the amplifica-
tion, followed by T-47D, which presented a chr 11 polysomy. The
lowest expression of AAMDC was detected in ER− tumor cell
lines and in non-transformed primary human mammary
epithelial cells (HuMEC) and MCF-12A cells. AAMDC was
found in both cytoplasmic and nuclear compartments, accom-
panied by plasma membrane staining depending on the cell line
analyzed (Fig. 1f).
Depletion of AAMDC expression inhibits BC cell growth and
migration. We investigated the role of AAMDC by lentiviral
transduction of three shRNAs in cell lines expressing high
AAMDC levels associated with the AAMDC amplification (MDA-
MB-134 and SUM52PE), or moderate levels (T-47D) associated
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22101-7
2 NATURE COMMUNICATIONS |         (2021) 12:1920 | https://doi.org/10.1038/s41467-021-22101-7 | www.nature.com/naturecommunications
with the chr 11 polysomy (Fig. 2a). The on-target specificity of
the most potent shRNA utilized in genomic and functional stu-
dies (AAMDC sh2) was validated by AAMDC cDNA rescue
experiments (Supplementary Fig. 1c). The AAMDC knockdowns
(KDs) inhibited cell proliferation (Fig. 2b) and impaired colony
formation in vitro (Fig. 2c), accompanied by a small but
significant increase in apoptosis (Supplementary Fig. 1e). Fur-
thermore, the AAMDC KDs reduced cell migration (Fig. 2d), a
finding consistent with altered F-actin organization (Fig. 2e) and
significantly decreased xenograft tumor burden in mice (Fig. 2f).
Analysis of DepMap CRISPR knockout screening data matched
with available molecular data from the Cancer Cell Line
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Encyclopedia (CCLE) provided independent confirmation that
the SUM52PE cell line with strong amplification and AAMDC
overexpression had a greater dependence on AAMDC for cell
survival relative to other luminal BC lines that do not harbor the
AAMDC amplification (Supplementary Fig. 1d).
In non-transformed mammary epithelial cells (HuMECs), even
the most potent AAMDC KDs produced only minor changes in
cell proliferation compared to the changes in cancerous IntClust2
cell lines, thus suggesting that IntClust2 cells are more dependent
on AAMDC expression (Supplementary Fig. 2a). However,
AAMDC cDNA overexpression did not activate cell migration
in poorly migratory cells (Supplementary Fig. 2b) nor did it
induce anchorage independence in HuMEC and primary adult
human dermal fibroblasts (HDFa) (Supplementary Fig. 2c).
Since bovine and murine pre-adipocytes can be differentiated to
induce lipid production by AAMDC cDNA overexpression12,13,
we also investigated whether AAMDC could regulate lipogenesis
in human cells. In SUM52PE cells, the AAMDC KD significantly
reduced the percentage of Oil Red O+ cells, thus suggesting that
AAMDC may control the accumulation of neutral lipids. In
contrast, the AAMDC cDNA did not significantly induce
lipogenesis in HuMECs (Supplementary Fig. 2d).
AAMDC controls transcription of multiple metabolic enzymes.
RNA-sequencing (RNA-seq) in SUM52PE cells transduced with
AAMDC sh2 revealed that the AAMDC KD differentially down-
and upregulated 1151 and 839 annotated genes, respectively (log2
fold-change, q < 0.05) relative to empty vector (EV) and
untransduced cells (Supplementary Data 2). Gene ontology (GO)
analyses of the significantly regulated targets indicated strong
involvement of AAMDC in cell death; the cell cycle; small GTPase
signaling; and various metabolic processes, including lipid,
nucleotide, and amino acid biosynthesis (Fig. 3a, Supplementary
Data 2). Network analysis of the differentially regulated targets
revealed two functional clusters, one associated with cell pro-
liferation (enriched in cell cycle genes) and the other with
metabolism (Fig. 3b). The metabolic cluster, comprising more
than 119 enzymes, was centered on a core of 26 carbon meta-
bolism enzymes including several one-carbon (1C)/folate meta-
bolism enzymes (all downregulated by the KD) that included
MTHFD1L (methylenetetrahydrofolate dehydrogenase (NADP+
Dependent) 1-like)) encoding a key metabolic enzyme linking
mitochondrial and cytoplasmic elements of mammalian 1C
metabolism (Fig. 3c). Not only did the KD of AAMDC down-
regulate MTHFD1L (Fig. 3d), but the KD of MTHFD1L also
inhibited cell proliferation, without affecting AAMDC expression,
thus suggesting that AAMDC acts upstream of MTHFD1L
(Fig. 3e).
Comprehensive metabolomic profiling of AAMDC sh2 and
controls by high-resolution liquid chromatography-mass spectro-
metry in SUM52PE cells revealed strong downregulation of the
synthesis of nucleosides (deoxycytidine and inosine), amino acids
(including proline, serine, and glycine), and metabolites asso-
ciated with cellular gluco-energetics (malate and lactate; Fig. 3f
and Supplementary Data 3). Interestingly, ophthalmic acid, which
may be an indicator of oxidative stress associated with the
metabolic depletion of glutathione14, was significantly upregu-
lated by the AAMDC KD. The most significantly downregulated
metabolite was cystathionine, the product of the enzymatic
reaction catalyzed by cystathionine-β-synthase (CBS), which is an
enzyme that converts homocysteine and serine to cystathionine in
the methionine cycle and which is hence necessary for the
synthesis of cysteine (Fig. 3c). These data confirmed that AAMDC
regulates enzymes involved in the folate and methionine cycles of
1C metabolism such as MTHFD1L and CBS, respectively.
AAMDC regulates PI3K-AKT-mTOR, leading to translational
control of oncogenic TFs. Since the PI3K-AKT-mTORC1 axis is
fundamental for the control of cell proliferation and
metabolism15–18, we next investigated whether AAMDC can
modulate this signaling pathway. The AAMDC KDs inhibited
activation of AKT relative to controls, as indicated by a reduction
in p-S473 and p-T308 levels, accompanied by a decrease in
MTHFD1L expression (Fig. 4a). We also observed decreased
levels of p-PDK1 S241 and p-TSC2 T1462 and a reduction in the
levels of p-4E-BP1 T37/46 and p-P70S6K T389, which are
downstream targets of mTORC1. The total protein (but not the
mRNA) levels of MYC and ATF4 were also downregulated in the
AAMDC KDs. Since ATF4 and MYC are translationally regulated
by 4E-BP116,19, this suggests that AAMDC similarly controlled
the translation of oncogenic transcription factors (TFs) at least in
part via canonical PI3K-AKT-mTORC1 signaling.
We next investigated whether TSC2 depletion could prevent
the effects of AAMDC on PI3K-mTOR signaling. SUM52PE cells
were first transduced with either EV or TSC2 shRNA, and
subsequently transduced with either EV or AAMDC shRNA. The
Fig. 1 AAMDC overexpression and amplification are associated with a subgroup of ER+ breast cancer with poor prognosis. a Analysis of somatic
alterations of AAMDC using cancer genomic data sets and tools available from cBioPortal (see “Methods”). The frequency of amplification is shown as a
percentage and the sample numbers are shown in brackets. METABRIC Molecular Taxonomy of Breast Cancer International Consortium, TCGA The
Cancer Genome Atlas, BRCA Breast Cancer, INSERM Institut national de la santé et de la recherche médicale, MBC Metastatic Breast Cancer, NSCLC non-
small-cell lung carcinoma, FHCRC Fred Hutchinson Cancer Research Center, NEPC National Environment Protection Council, PanCan Pan-Cancer.
b Kaplan–Meier survival plots for patients with tumors expressing high (red) or low (green) levels of AAMDC mRNA. The lower left plots correspond to
luminal B tumors treated with tamoxifen (see “Methods”). The p value shown for each plot is determined by the log-rank test. GEO Gene Expression
Omnibus, GSE genomic spatial event, NSCLC non-small-cell lung carcinoma. c Localization of the AAMDC protein in tumors from a breast tissue
microarray (TMA) assessed by immunohistochemistry (IHC). Representative IHC sections of normal breast tissue, estrogen receptor-negative (ER−)
tumor tissue, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) are shown. 0, 1+, 2+, 3+ indicate the staining intensity score.
d Associations between AAMDC expression (IHC) and lymph node metastasis (LN+) as well as tumor grade, tumor size (T3-4), and ER positivity (ER+)
by AAMDC localization from the same TMA. Statistical significance is indicated by Chi-square analysis with a one-tailed p-value relative to ER− tissue. For
T3-4: *p= 0.03; for LN+: *p= 0.03; for ER+, from left to right: *p= 0.003, *p= 0.005, *p= 0.005. n= 60 biologically independent samples. Full details of
the TMA are provided in Supplementary Table 1. e Frequency of AAMDC amplification/polysomy in a cohort of 119 luminal B breast cancer specimens.
Representative fluorescence in situ hybridization (FISH) images are indicated, with specific probes for AAMDC (red) and Centromere enumeration 11 probe
for chromosome 11 (C11, green). The full clinical and pathological features of these tumors are shown in Supplementary Data 1. f Real-time expression
analyses (qRT-PCR) of AAMDC in luminal, non-luminal, and normal-like breast cells. Significance levels are determined relative to MCF-12A by Ordinary
one-way ANOVA with Dunnett multiple comparison test. Data are presented as mean values ± SEM (*p= 0.0217, **p= 0.0018, ****p < 0.0001). n= 3
biologically independent RNA extractions. Representative images of immunocytochemistry (ICC) and FISH of selected luminal cell lines are presented.
HuMECs non-transformed human mammary epithelial cells.
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TSC2 KD partially reduced the endogenous TSC2 levels, and this
was concomitant with a higher level of p-4E-BP1 relative to total
4E-BP1, thus indicating that TSC2 KD induced mTORC1 signaling.
This was also confirmed by increased MYC and p-4E-BP1 levels
downstream of mTORC1. However, the TSC2 KD did not
completely prevent the effects of AAMDC KD on the
phosphorylation of 4E-BP1 and MYC downregulation (Supple-
mentary Fig. 3a). We also observed a reduction in the
phosphorylation of another AKT-specific target, p-FOXO 1/3
(T24/32), which is not a substrate of mTORC1. Thus, AAMDC
could act upstream of AKT to regulate several pathways, inclusive
of but not exclusive to mTORC1 signaling (Fig. 4a).
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While decreases in p-mTOR S2448 and TSC2 levels were
confirmed by confocal microscopy, the intracellular localization
of p-mTOR S2448 and TSC2 was not altered by the AAMDC KD,
nor did we observe differences in the colocalization with
lysosome-associated membrane protein 2 (LAMP2) (Supplemen-
tary Fig. 3b, top). Similarly, the intracellular localization of the
p110α catalytic subunit of PI3K was not perturbed by the
AAMDC KD (Supplementary Fig. 3b, bottom). However,
LAMP2, and to a lesser extent the early endosomal marker
EEA1, appeared to be more clustered in the AAMDC KD
compared to the control cells. Strikingly, the AAMDC KD
induced enlarged LAMP2+ late endosomal vesicles, which
exhibited a degree of positive staining for p-mTOR S2448
(Supplementary Fig. 3b) and fibroblast growth factor receptor 2
(FGFR2), which is overexpressed in IntClust2 SUM52PE cells and
confers activation of PI3K20 (Supplementary Fig. 7b). While
requiring further investigation, this lysosomal phenotype also
points to decreased mTORC1 signaling induced by the
AAMDC KD.
Furthermore, pharmacological inhibition of PI3K-AKT-mTOR
in SUM52PE cells by dactolisib (a dual mTORC1/2 and PI3K
inhibitor), AZD8055 (an mTORC1/2 inhibitor), everolimus (an
mTORC1 inhibitor), and buparlisib (a PI3K inhibitor) mimicked
the effects of the AAMDC KDs in terms of downregulation of
PI3K-AKT-mTOR. These inhibitors similarly reduced the levels
of ATF4, MYC, and MTHFD1L. Furthermore, AKT activation
was decreased by all of the inhibitors except everolimus (an
anticipated difference as it acts downstream of mTORC2 and
PDK1), thus suggesting that mTORC1 is at least sufficient to
regulate MTHFD1L levels (Fig. 4b).
Pharmacological blockade of PI3K-AKT-mTOR also phe-
nocopied the effect of the loss-of-function of AAMDC in terms
of downregulation of transcription of selected cell cycle, DNA
replication, and metabolic targets (Fig. 4c) discovered in our
RNA-seq (Fig. 3). In particular, dactolisib was at least as effective
as the other inhibitors in suppressing target gene expression and
significantly more effective for particular targets (e.g., PHGDH;
Fig. 4c). Both dactolisib and depletion of AAMDC reduced the
binding occupancy of ATF4 and MYC to the promoters of two
selected downregulated genes, ASNS and MTHFD1L, compared
to control promoters lacking binding sites for these TFs (ACTB;
Fig. 4d). These results suggest that AAMDC controls the protein
levels and consequently the binding occupancy of oncogenic TFs
in their targeted promoters.
The genomic selectivity of AAMDC relative to that of the
PI3K-mTOR inhibitors was examined by comparative transcrip-
tomics in SUM52PE cells (Fig. 5a). The RNA-seq from the
AAMDC KD was analyzed in parallel with drug-treated samples
(dactolisib, everolimus, AZD8055, or buparlisib) to enable cross-
examination of differentially expressed genes (DEGs). We found a
stronger trend for DEGs in dactolisib-treated cells to up- or
downregulate in the same direction as the DEGs in the AAMDC
KD, thus suggesting similar downstream targets, compared to the
other inhibitors that were tested (Fig. 5b).Various metabolic
processes were enriched in the gene ontology (GO) term analysis
for genes commonly downregulated between the KD and at least
three of the drug treatments (Fig. 5c, Supplementary Fig. 4,
Supplementary Data 4). Upregulated GO terms included regula-
tion of cell proliferation and transcription (Fig. 5c). Gene set
enrichment analysis also revealed depletion of mTORC1 signaling
and MYC target genes in the AAMDC KD and all of the drug-
treated samples (Fig. 5d–e, Supplementary Data 4). Interestingly,
although ER response genes were depleted in the AAMDC KD
and dactolisib-treated cells, we observed an opposite trend,
namely upregulation of ER and AR response genes, in cells
treated with everolimus, AZD8055, and buparlisib (Fig. 5f).
Among the AAMDC-specific genes (Supplementary Fig. 5,
Supplementary Data 4), we identified unique targets involved in
PI3K-dependent vesicle trafficking and lysosomal degradation of
cellular receptors, thereby substantiating a role of AAMDC in the
regulation of endosomal trafficking.
AAMDC overexpression activates AKT signaling and induces
estrogen-independent tumor growth in vivo. Consistent with
the model of action of AAMDC, insulin, fetal bovine serum (FBS),
amino acids, and tumor necrosis factor α (TNF-α) activated AKT
signaling, thereby increasing MTHFD1L expression (Fig. 6a).
Treatment of insulin-dependent SUM52PE cells with insulin
partially rescued the effects of AAMDC KD, as assessed by
detection of p-AKT S473 and MTHFD1L by immunoblotting
(Supplementary Fig. 3c). Similarly, estrogen (β-estradiol, E2) led
to fast and strong activation of this pathway in ER+ SUM44PE
IntClust2 cells, thus suggesting a non-genomic effect, with a
Fig. 2 AAMDC knockdown in luminal breast cancer cells inhibits tumorigenic and migratory capacity. a Detection of AAMDC expression in luminal
breast cancer cells with the AAMDC amplification (SUM52PE and MDA-MB-134) or the chromosome 11 polysomy (T-47D). Cells were transduced with
either the AAMDC shRNAs #1–#3 or with empty vector (EV) and processed by qRT-PCR (top) and immunoblotting (bottom). Wild-type (WT) indicates
untransduced cells. Data are normalized to the EV control and presented as mean values ± SD. p-values are determined by two-tailed unpaired t-test
(SUM52PE: ***p= 0.0003, ****p < 0.0001; MDA-MB-134: ***p= 0.0004, ****p < 0.0001; T-47D: *p= 0.0142 and *p= 0.0107 for EV and shRNA #3
respectively, ****p < 0.0001). n= 3 biologically independent experiments. Source data are provided as a Source Data file. b Cell proliferation assessed by α-
Ki-67 immunostaining (green), superimposed on nuclear Hoechst 33258 staining (blue). Data are normalized to the EV and presented as mean values ±
SD. p-values are determined by two-tailed unpaired t-test (SUM52PE: ****p < 0.0001; MDA-MB-134: **p= 0.0044, ***p= 0.0002, ****p < 0.0001; T-47D:
***p= 0.0001, ****p < 0.0001). n= 3 biologically independent experiments. c Inhibition of anchorage-independent cell growth by depletion of AAMDC
expression assessed by soft agar colony formation assay 28 days after transduction. Data are normalized to the EV and presented as mean values ± SD. p-
values are determined by two-tailed unpaired t-test (SUM52PE: *p= 0.0235, ****p < 0.0001; MDA-MB-134: *p= 0.0466, ****p < 0.0001; T-47D: **p=
0.0010, ***p= 0.0002, ****p < 0.0001). n= 3 biologically independent experiments. d Inhibition of cell migration as assessed by Boyden migration
chamber assays 24 h after transduction. Data are normalized to the EV and presented as mean values ± SD. p-values are determined by two-tailed unpaired
t-test (SUM52PE: **p= 0.0036, ***p= 0.0004, ****p < 0.0001; T-47D: ***p= 0.0002, ****p < 0.0001). n= 3 biologically independent experiments.
e Effect of the AAMDC knockdown (KD) on F-actin organization assessed by phalloidin fluorescence staining (Alexa Fluor 488, green), nuclei (Hoechst
33258, blue). In (b–e), representative images of SUM52PE cells transduced with EV or AAMDC shRNAs #1–#3 (sh1–3) are shown (left). In (a–d),
quantification for each cell line transduced with empty vector (EV, blue), shRNA #1 (orange), shRNA #2 (red), shRNA #3 (lilac), and untransduced (WT,
gray). f Tumor growth inhibition in vivo by AAMDC KD in the T-47D xenograft model in nude mice. Representative sizes of the tumors extracted from the
animals at day 10 post-injection of the cells are shown (left). Scatter dot plot outlining the decrease in tumor volume at day 3 and day 10 post-implantation
of the cells (right). EV, blue; sh2, red. Data are normalized to the EV and presented as mean values ± SEM. p-values are determined by two-tailed unpaired
t-test (***p= 0.0003, ****p < 0.0001), n= 8 mice per group.
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biphasic pattern resulting in peaks of activation after 30 and 420
min of exposure to the ligand (Fig. 6a). Of note, the endogenous
AAMDC levels were not modulated by treatment of ER+ cells
with E2, thus suggesting that AAMDC is not, in itself, an
estrogen-responsive gene (Supplementary Fig. 3d). Interestingly,
the exogenous levels of both AAMDC mRNA and protein were
greater in transgenic AAMDC-MCF-7 cells subjected to starva-
tion conditions compared to cells grown in complete medium
(Fig. 6a, right and 6b, left), thus suggesting the occurrence of
post-transcriptional feedback regulatory loops13. Overexpression
of the AAMDC cDNA in MCF-7 cells also resulted in constitutive
AKT activation, particularly in cells depleted of FBS, insulin, and
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E2, and thus the AAMDC cDNA activated the pathway in con-
ditions of nutrient deprivation or metabolic stress (Fig. 6a, right).
To assess the oncogenic function of AAMDC in vivo, we
injected MCF-7 cells overexpressing either AAMDC cDNA or EV
into immunodeficient mice (Fig. 6b). The tumor cells were
injected subcutaneously with low growth factor (LGF)-containing
Matrigel® and supplemented either with injections of 1 μg of E2
(20 μg/mL) every 3–4 days (+E2) or in the absence of
E2 supplementation (−E2). As expected, the EV tumors grew
in the +E2 condition but they failed to proliferate in the −E2
condition. In the +E2 conditions, the AAMDC-overexpressing
tumors only had significantly higher tumor volumes relative to
the controls at day 10 post-injection (Fig. 6b, top right). However,
in the −E2 condition, AAMDC significantly activated tumor
growth at all of the time points investigated and reached volumes
at day 55 post-injection comparable to those of tumors grown in
the +E2 condition (Fig. 6b, bottom right). The MCF-7-AAMDC
tumors sustained AAMDC overexpression even at day 55 post-
injection, with those in the E2-deprived conditions exhibiting
significantly greater levels of AAMDC mRNA than the +E2
tumors (Fig. 6b, middle).
Representative tumors resected at day 55 post-injection
confirmed the overexpression of AAMDC and its downstream
selected effectors p-AKT S473, MYC, and MTHFD1L. The
AAMDC cDNA sections exhibited more dense islands of tumor
cells and higher levels of Ki-67 (notably in the −E2 condition)
relative to the EV (Fig. 6c). Interestingly, the MCF-7-AAMDC
tumors in the −E2 condition exhibited a higher frequency of
nuclear MYC and p-AKT S473 staining than the +E2 tumors.
These results validated the oncogenic role of AAMDC in
activating PI3K-AKT-mTOR in vivo, particularly in conditions
of growth factor and E2 deprivation.
Pharmacological inhibition of AAMDC-dependent targets by
PI3K-mTORC1 blockers in combination with anti-estrogens.
We next investigated whether the effects of AAMDC could be
mitigated through combination treatment with PI3K-mTORC1
inhibitors and the ER modulator tamoxifen. Treatment of ER+
SUM44PE and MDA-MB-134 cells with tamoxifen in combina-
tion with everolimus or dactolisib resulted in greater inhibition of
AKT signaling and MTHFD1L expression than with either drug
alone (Fig. 7a).
In addition, the dual PI3K-mTOR inhibitor dactolisib more
potently inhibited cell viability than the mTORC1-specific
inhibitor everolimus, particularly in the ER+ IntClust2 cell line
MDA-MB-134, which showed the highest level of endogenous
AAMDC (Figs. 1f, 7f, right) and exhibited resistance to tamoxifen
alone across all concentrations tested (Fig. 7b–d). Moreover, we
observed highly synergistic pharmacological interactions between
these PI3K-mTOR inhibitors with tamoxifen in IntClust2 cell
lines, with combination indexes (CIs) < 1 (Fig. 7e). Furthermore,
overexpression of AAMDC in MCF-7 cells also increased the
sensitivity to dactolisib and, to a lesser extent, everolimus, but not
to the non-selective cytotoxic drug docetaxel (Fig. 7f).
AAMDC binds to the GTPase-activating protein RabGAP1L.
To determine the direct binding partners of AAMDC, we con-
ducted two independent yeast two-hybrid (Y2H) screens using
bait plasmids N-LexA-AAMDC-C and N-Gal4-AAMDC-C and a
cDNA library from luminal BC cells. We identified RabGAP1L
(Rab GTPase-activating Protein 1-like) as a high-confidence prey,
being the only target identified in both independent screens
(Supplementary Data 5). RabGAP1L is a signal transduction
protein that binds and regulates Rab GTPases, thereby controlling
protein trafficking21.
Both RabGAP1L and AAMDC were co-expressed on the
plasma-membrane, in the cytoplasm, and/or in the nucleus of
luminal cancer cells, as assessed by IF (Fig. 8a). A similar pattern
of costaining, both in terms of intensity and intracellular
localization, was observed in serial full-face sections taken from
clinical breast tissue specimens, as assessed by IHC (Fig. 8b).
The Y2H experiments revealed that the minimal interaction
domain of AAMDC comprised the phosphotyrosine binding
(PTB) domain of RabGAP1L (Supplementary Data 5) and,
consistent with this, AAMDC contains a PTB binding consensus
motif (NTTY). In contrast, RabGAP1L binds small Rab GTPases
via its highly conserved Tre-2/Bub2/cdc16 (TBC) domain
(Fig. 8c).
We next investigated the interactions between AAMDC and
RabGAP1L and a subset of selected Rabs: Rab13, Rab22a, Rab7a,
and Rab35. Rab13 and Rab22a were chosen as they are known
interactors of RabGAP1L21,22, while Rab7a was captured as a
binding partner of AAMDC22. Similar to AAMDC, oncogenic
Rab35 constitutively activated p-AKT S473 in a ligand-
independent manner23.
Immunoprecipitations (IPs) with tagged constructs in
HEK293T cells confirmed that HA-RabGAP1L can bind FLAG-
AAMDC, and that HA-RabGAP1L can be found associated with
selected Myc-Rab proteins (particularly Rab7a, as shown in
Fig. 8d, as well as Rab13 and Rab35, see Supplementary Fig. 6a).
Reciprocal IPs with α-HA-RabGAP1L beads failed to capture
AAMDC and/or Rab proteins, which could be due to steric
inaccessibility of their binding epitopes in the RabGAP1L pull-
downs (Supplementary Fig. 6c and d). In the absence of
RabGAP1L expression, no direct interaction between the Rabs
and AAMDC was observed (Fig. 8d, Supplementary Fig. 6a).
Fig. 3 AAMDC regulates targets involved in cell proliferation and metabolism. a Gene ontology (GO) analyses of the top 10 biological processes (sorted
by Modified Fisher Exact p-value, EASE score by DAVID) identified by analysis of differentially regulated genes as assessed by RNA-seq of SUM52PE cells
transduced with AAMDC shRNA #2 (sh2) compared with empty vector (EV) (Supplementary Data 2). b Network analysis (STRING, v11) outlining
interactions between differentially regulated targets. MTHFD1L is outlined in red. c Schematic representation of 1C metabolism (folate and methionine
cycles) and amino acid biosynthesis (serine and asparagine) pathways. Genes regulated by AAMDC (as per RNA-seq) are depicted in dark blue. 3PHP 3-
phosphohydroxypyruvate, 3PS 3-phosphoserine, 3PG 3-phosphoglycerate, THF tetrahydrofolate, TCA tricarboxylic acid cycle. d Representative
immunoblots (IB) showing the reduction of MTHFD1L protein expression by the AAMDC knockdowns (KDs) shown in Fig. 2a. Source data are provided as a
Source Data file. e Knockdown of MTHFD1L by shRNA decreased cell proliferation in SUM52PE cells. Protein levels are assessed by IB (top) and cell
proliferation by α-Ki-67 staining (green); Hoechst 33258-stained nuclei (blue). WT wild-type (untransduced cells), EV empty vector, MTHFD1L shRNAs
#1–#2 (sh1–2). Representative images are shown (middle). Quantification is shown in bottom panel: WT (gray), EV (blue), shRNA #1 (orange), shRNA #2
(red). The relative quantification of Ki-67+ cells is normalized to EV and presented as mean values ± SD. p-values are determined by two-tailed unpaired t-
test (**p= 0.0039, ****p < 0.0001). Fields of view examined: n= 7 for EV, n= 9 for WT and sh1, and n= 10 for sh2 over 2 independent experiments (right
panel). f The top 25 significantly differentially regulated metabolites (WT vs. AAMDC sh2; p < 0.05, two-tailed unpaired t-test) identified by liquid
chromatography-mass spectrometry (LC-MS) in SUM52PE cells stably transduced with either AAMDC sh2 or EV. n= 3 biologically independent
experiments.
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Moreover, when the three plasmids (FLAG-AAMDC/HA-Rab-
GAP1L/Myc-Rab) were co-transfected, pull-downs with α-FLAG-
AAMDC confirmed the association between AAMDC and
RabGAP1L. Pull-downs by α-Myc-Rab-coated beads resulted in
a much weaker capture of HA-RabGAP1L (Fig. 8d; Supplemen-
tary Fig. 6a). Thus, in these assays, AAMDC overexpression could
influence the binding and/or dissociation of certain Rab proteins
from RabGAP1L, but this will require further experiments for
validation.
Subsequent IPs showed that RabGAP1L and AAMDC bound
Ankyrin-B (AnkB), which has been shown to recruit RabGAP1L
in PI3P+ vesicles21 (Supplementary Fig. 6e). Regions of AAMDC-
AnkB overlap were predominant near the plasma membrane
and in the cytoplasm, as assessed by confocal microscopy
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(Supplementary Fig. 6f). Live-cell microscopy confirmed several
regions of overlap between 2xFYVE N-terminally fused to
mCherry, a marker of phosphatidylinositol 3-phosphate (PI3P)
with eGFP-RabGAP1L, thereby providing evidence that Rab-
GAP1L may colocalize, at least in part, in PI3P+ vesicles, some of
which were Rab7a+ late endosomes (Supplementary Fig. 7a).
Deletion of the PTB domain of RabGAP1L [HA-
RabGAP1LΔPTB(471)] suppressed the interaction between
AAMDC and RabGAP1L, as assessed by IPs in HEK293T cells,
but retained the RabGAP1L-Rab interactions (Fig. 8e, Supple-
mentary Fig. 6b). In contrast, deletion of the TBC domain [HA-
RabGAP1LΔTBC(585)] suppressed both the interaction between
RabGAP1L and AAMDC as well as the binding of Rab proteins
(Fig. 8f, Supplementary Fig. 6b).
To analyze the physical proximity of AAMDC, RabGAP1L, and
Rab proteins in intact cells we conducted Bioluminescence
Resonance Energy Transfer (BRET) experiments. HEK293FT cells
were co-transfected with luciferase-tagged AAMDC (RLuc8-
AAMDC), fluorophore-tagged Rabs (Venus-tagged Rabs), and either
untagged full-length RabGAP1L, RabGAP1LΔPTB, or Rab-
GAP1LΔTBC. Co-transfection of AAMDC, RabGAP1L, and selected
Rabs resulted in a consistently greater BRET signal compared to that
of AAMDC in the absence of RabGAP1L (control). Transfection of
RabGAP1LΔPTB or RabGAP1LΔTBC produced a decay in BRET
signal relative to the full-length RabGAP1L, particularly with Rab7a,
Rab22a, and Rab35 (Fig. 8g and Supplementary Fig. 8a).
Further IF assays with transfected HEK293T cells provided
evidence that the RabGAP1L staining could overlap with that of
Rab7a (Supplementary Fig. 8b), which is a finding consistent with
our live-cell imaging (Supplementary Fig. 7a). In contrast,
RabGAP1LΔPTB and RabGAP1LΔTBC exhibited a more diffuse
cytoplasmic pattern of expression, with negligible areas of overlap
with Rab7a, in accordance with the BRET data (Supplementary
Fig. 8b).
Lastly, we investigated the dependency of the AAMDC-
RabGAP1L interaction in activating AKT signaling. We found
that RabGAP1L KD in SUM52PE cells had similar effects as the
AAMDC KD, reducing p-AKT S473 and MTHFD1L levels
(Supplementary Fig. 9a). Furthermore, lentiviral overexpression
of RabGAP1LΔPTB and AAMDC-DAAE, which has the PTB
binding consensus sequence 20-NTTY-23 mutated to DAAE
reduced AKT signaling (Supplementary Fig. 9b). The Rab-
GAP1LΔPTB mutant phenotype, however, was mild and
reversible and it progressively reverted towards a phenotype
sensitive to the effects of the AAMDC KD (Supplementary
Fig. 9c), which could be due to competition between the
RabGAP1L mutant transgene with the endogenous gene. In
addition, both RabGAP1LΔPTB and AAMDC-DAAE, but not WT
RabGAP1L and AAMDC cDNAs, phenocopied the effects of the
AAMDC KDs in inducing F-actin remodeling (Supplementary
Fig. 9d). These experiments indicated that functional effects of
AAMDC KDs could be phenocopied by suppression of
RabGAP1L expression or by alteration of its predicted binding
interfaces with AAMDC.
In summary, our results indicate that AAMDC constitutively
activates PI3K-AKT-mTORC1 signaling to support tumor
growth, notably under conditions of metabolic stress such as
growth factor and E2 deprivation. We propose that AAMDC
regulates the translation of oncogenic TFs such as MYC and
ATF4, which in turn could control the transcription of several
target genes involved in cell cycle control and metabolism
(Supplementary Fig. 10). We also describe AAMDC-RabGAP1L
physical interactions that could mediate some of the functional
facets of AAMDC for induction of AKT signaling, thereby
highlighting potentially druggable interfaces for future therapeu-
tic intervention.
Discussion
Herein, we have unveiled the function of AAMDC, an oncogene
selectively amplified in ~25% of luminal B BCs, which often
exhibit anti-E2 resistance and very poor prognoses24,25. We
propose that AAMDC orchestrates the coordinate control of
proliferation and metabolism by regulating the PI3K-AKT-
mTOR signaling axis. The AAMDC KDs inhibited the transla-
tion and thereby the promoter occupancy of MYC and ATF4 at
the AAMDC-responsive promoters. Notably, we show that
AAMDC is involved in the regulation of the expression of
enzymes participating in the folate and methionine cycles of 1C
metabolism (such as MTHFD1L, ASNS, SHMT2, and CBS) and in
lipid metabolism. Supporting our model, there is abundant evi-
dence that mTORC1 regulates the cap-dependent translation of
MYC15,19,26–28 and ATF416,29, and that mTORC1 modulates
metabolic genes transcription16,29–31.
Our findings illuminate metabolic vulnerabilities that could be
therapeutically exploited, more specifically, to target the malig-
nancies carrying the AAMDC amplification. Excitingly, the
metabolite most downregulated by AAMDC KD was cystathio-
nine, which is a product of the CBS enzyme involved in the
methionine cycle and implicated in tumor survival in breast
cancer32 and lipid metabolism in ovarian cancer33. In addition,
the effects of AAMDC KD in normal breast epithelial cells were
mild, thus suggesting that IntClust2 cells could be more addicted
to AAMDC expression.
Our comparative transcriptomics data suggests that AAMDC
KD is more similar to the dual PI3K-mTOR blocker dactolisib
than to single PI3K and mTOR blockers. Moreover, our rescue
experiments highlighted that the AAMDC effects are mediated by
but not exclusively to mTORC1. This finding was reinforced by
our RNA-seq data that also pointed to unique AAMDC targets
Fig. 4 AAMDC knockdowns downregulate the PI3K-AKT-mTOR axis through translational suppression of MYC and ATF4 leading to transcriptional
downregulation of AAMDC-dependent targets. a Regulation of the PI3K-AKT-mTOR pathway in SUM52PE cells transduced with AAMDC shRNAs
assessed by immunoblotting. WT wild-type (untransduced cells), EV empty vector. Source data are provided as a Source Data file. b Modulation of the
PI3K-AKT-mTOR pathway by pharmacological inhibition. SUM52PE cells were treated for 24 h with the indicated PI3K-AKT-mTOR inhibitors. Source data
are provided as a Source Data file. c Transcriptional regulation of selected AAMDC-dependent transcripts involved in cell cycle and epigenetic regulation
(left) and metabolic control (right). The results are normalized to vehicle-treated cells. Statistical significance is determined by multiple t-test using the
Holm-Sidak method with alpha= 0.001 (left) and alpha= 0.05 (right), and presented as mean values ± SD, *p < 0.0001. n= 3 biologically independent
experiments. d, Decreased promoter occupancy of ATF4 and MYC transcription factors at predicted promoter sites in two AAMDC targets: ASNS and
MTHFD1L determined by promoter-specific chromatin immunoprecipitation (ChIP). SUM52PE cells are transduced with either empty vector (EV) or with
AAMDC shRNA #2 (sh2), or treated with either vehicle control or 100 nM dactolisib (24 h). The position of ATF4 and MYC and the primers used for
quantification are shown (top). Enrichment is determined by qRT-PCR and normalized to control cells and presented as mean values ± SEM. p-values are
determined by two-tailed unpaired t-test. For ASNS promoter: *p= 0.0102 and *p= 0.0447 for dactolisib and sh2, respectively; **p= 0.0019, ***p=
0.0003. For MTHFD1L promoter: *p= 0.0201. n= 3 biologically independent experiments. TSS transcription start site, F forward, R reverse.
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involved in catabolic metabolism of cellular receptors, lysosome/
vacuole organization, and endosomal trafficking, thereby further
highlighting more specific biological features induced
by AAMDC.
In vivo, AAMDC overexpression was sufficient to activate the
growth of E2-dependent tumor cells under metabolic stress
conditions (low levels of growth factor and E2 deprivation). This
was accompanied by activation of AKT signaling in vivo, with
greater nuclear localization of p-AKT S473 and MYC relative to
control tumors. It is known that constitutive activation of AKT
leads to E2-independent tumor growth in vivo34–36, and that
breast cancer cells adapt to long-term E2 deprivation with
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increases in PI3K-AKT activity, thereby becoming dependent on
PI3K signaling for growth37. Our findings suggest a role of
AAMDC as a molecular metabolic switch whereby upregulation
of AAMDC through copy number amplification could help sus-
tain ligand-independent activation of PI3K-AKT, and thus sup-
porting tumor survival under metabolic stress conditions, such as
E2 deprivation. This mechanism could potentially be of great
significance in patients undergoing anti-E2 treatments.
Importantly, we suggest that some oncogenic facets of
AAMDC for activation of AKT may be dependent on the inter-
action between AAMDC and the PTB domain of RabGAP1L.
Further, we present evidence that AAMDC, RabGAP1L, and
Rab7a could be localized in endolysosomes, which would provide
them with an opportunity to interact. Likewise, there is potential
for AAMDC and RabGAP1L to associate with additional Rabs, as
suggested by our biochemical and BRET data, but this remains to
be verified based on colocalization and other approaches.
Future investigation will be required to elucidate the exact
molecular mechanism of action by which AAMDC activates the
PI3K-AKT-mTOR pathway. Small GTPases are implicated in
multiple aspects of PI3K and mTOR regulation23,38–44. In this
context, the AAMDC-RabGAP1L complex could play a role in
the regulation of vesicle trafficking, potentially altering the recy-
cling of small G proteins and thus remodeling the cancer sig-
naling network. These effects could also explain the multiple
differential localizations of AAMDC and RabGAP1L in human
tumors. It is conceivable that AAMDC could modulate AKT
signaling by alteration of the association or release of particular
Rab proteins from RabGAP1L, and potentially modulating their
intrinsic GTPase activity. The enlarged LAMP2+ vesicles induced
by the AAMDC KDs that stained positive for p-mTOR S2448 and
FGFR2 supports a mechanism of aberrant mTOR signaling
through impaired lysosome function via degradation of cellular
receptors, such as FGFR2.
Ras-like Rab oncoproteins45 are traditionally considered
difficult-to-drug and thus our work opens up new avenues for the
development of informed treatments for these aggressive
BCs24,25. We found that combination treatments of dactolisib or
everolimus with tamoxifen also decreased cell viability in a highly
synergistic manner in IntClust2 ER+ cell lines expressing high
levels of AAMDC. The activity of everolimus in combination with
anti-E2 therapy in clinical trials is such that it is now used rou-
tinely with anti-estrogens in the setting of metastatic BC resistant
to anti-E2 treatment alone46. However, the failure of translational
studies to find an effective biomarker of activity47, in combination
with the relatively high toxicity associated with the drug, has
precluded both wider use in the metastatic setting as well as
progression of this combination to adjuvant trials. In regard to
dactolisib, there is pre-clinical evidence of synergy with anti-
estrogens48, although again the toxicity profile is such that a
biomarker of efficacy is likely to be required to obtain a viable
therapeutic profile for routine usage49. In this context, our work
indicates that AAMDC could just be such a biomarker and that
targeting AAMDC signaling with PI3K-AKT-mTOR inhibitors
and potentially more specifically, targeting key binding interfaces
with effectors (such as the PTB domain of RabGAP1L), may be
an effective and more selective treatment for IntClust2 cancers or
other malignancies that have AAMDC amplification.
Methods
Additional information of key resources used for undertaking this study is pro-
vided in Supplementary Data 6.
Human studies. The immunohistochemistry (IHC) of estrogen receptors, as well
as the AAMDC gene amplification studies by FISH, were performed on a total of
119 samples. All of the patients were women between 31 and 91 years of age.
Luminal B tumors were defined either by ER and HER2 co-expression or by a high
tumor grade in ER-expressing malignancies. The study was approved by the
medical review board of the Medical University of Gdansk (NKBBN/205/2017).
Informed consent for the acquisition and the use of patient’s samples was obtained.
Animal studies. The animal experiments were performed in accordance with the
protocols approved by the Animal Ethics Committee of the University of Western
Australia (RA/3/100/1159 and RA/3/100/1687). Five-week-old female BALB/cJ
Foxn1nu/Arc (Nude mice) were obtained from the Animal Resources Centre
(Canning Vale, Australia) and used for the breast cancer xenograft growth study.
All animals received adequate environment enrichment, which includes housing
with other animals where possible. Mice were housed in Techniplast GM500 cages
(30 cm × 16.7 cm × 13.5 cm) (n= 4/cage) on a coarse aspen bedding with a paper
towel, a tissue, a cotton nestlet, and an aspen gnawing block for enrichment. Room
temperature and humidity was maintained at 22.5 °C and between 30% and 70%,
respectively. All mice were held under 12:12 (12-h light:12-h dark) with light
increasing gradually in both the morning and evening. The mice were randomly
assigned to the different experimental groups.
Oncogenomic datasets and portals. Analysis of somatic alterations for the
AAMDC gene (Fig. 1a) was performed by examination of cancer genomic datasets








survival analyses of the cancer patients with high and low expression levels of
AAMDC (Fig. 1b) were performed with the PPISURV portal50,52 (http://www.
bioprofiling.de/GEO/PPISURV/ppisurv.html). The survival analyses of breast, ovar-
ian, and lung cancer patients were performed by investigating the GSE11121,
GSE13876, and GSE19188 GEO datasets, respectively. Survival of Luminal B patients
treated with tamoxifen with high and low expression of AAMDC was compared using
Kaplan–Meier plotter server53 and the GEO datasets: GSE12093, GSE16391,
GSE17705, GSE19615, GSE26971, GSE2990, GSE3494, GSE37946, GSE45255,
GSE6532, and GSE9195.
Fig. 5 AAMDC knockdown and PI3K-AKT-mTOR inhibitors regulate the transcription of genes involved in common biological processes. a Volcano
plots showing differentially expressed gene (DEG) transcripts in AAMDC shRNA #2 (sh2) vs. empty vector (EV) and dactolisib, everolimus, AZD8055, and
buparlisib vs. dimethyl sulfoxide (DMSO) vehicle controls (left to right panels). Significantly upregulated DEGs, log2fold-change (log2FC) > 1, Padj. < 0.05,
are depicted in red and significantly downregulated DEGs (log2FC <−1, Padj. < 0.05) in green. b Scatter plots outlining the distribution of all significant
DEGs (Padj. < 0.01) in EV vs. WT (wild-type) control (y-axis) against AAMDC sh2 vs. EV (x-axis) and dactolisib, everolimus, AZD8055, and buparlisib vs.
DMSO controls (y-axis) against AAMDC sh2 vs. EV (x-axis) (left to right panels). A linear model is shown (green line) (R2 indicating model fit) and the
Spearman correlation (rS) between the outlined conditions. Color represents gene density within that region of the plot: low density (black) to high density
(yellow). c Gene ontology (GO) analysis of 186 downregulated and 123 upregulated genes (Padj. < 0.01) that are common in the AAMDC sh2 sample for at
least three of the drug treatments. The top 10 biological processes are ranked by the p-values. d Gene set enrichment analysis (GSEA) plot of
mTORC1 signaling targets shown in Supplementary Data 4 in AAMDC sh2 compared with EV, as well as dactolisib, everolimus, AZD8055, and buparlisib
compared with DMSO control (Ctrl) (left to right panels). The y-axis and the green line show the enrichment score for each gene, illustrated as a vertical
line plotted in rank order of the most gene abundance (red, left) to the least gene abundance (blue, right) within the indicated samples (as log2FC/
comparison); the black vertical lines correspond to member genes from the set. NES normalized enrichment score, FDR false discovery rate. e As in (d) for
the MYC target genes shown in Supplementary Data 4. f As in (d) for the estrogen-responsive genes shown in Supplementary Data 4.
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Molecular modeling. Molecular modeling of the bacterial and human AAMDC
protein structures was performed with Phyre2 (v2.0). Protein Data Bank (PDB)
structures shown in Fig. 8 are available under the accession codes IHN https://doi.
org/10.2210/pdb1IHN/pdb54 and 2AB1, https://doi.org/10.2210/pdb2AB1/pdb55.
Cell culture. All of the cell lines used in the study were authenticated,Mycoplasma-
free and commercially available. All of the cells were cultured at 37 °C in a 5% CO2
incubator in a humidified atmosphere. The MDA-MB-231 and HEK293T cells
were grown in DMEM high glucose-pyruvate medium containing 10% FBS and 1%
antibiotic-antimycotic. The HEK293FT cells were cultured in DMEM containing
0.3 mg/mL glutamine, 100 IU/mL penicillin, and 100 μg/mL streptomycin supple-
mented with 10% fetal calf serum (FCS) and 400 μg/mL Geneticin (Thermo Fisher
Scientific). The MDA-MB-134 cells were cultured in DMEM high glucose-pyruvate
medium supplemented with 20% FBS and 1% penicillin-streptomycin. The MCF-7
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22101-7 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:1920 | https://doi.org/10.1038/s41467-021-22101-7 | www.nature.com/naturecommunications 13
cells were grown in MEM alpha medium containing 10% FBS, 1% sodium pyr-
uvate, 1% sodium bicarbonate, 1% non-essential amino acids and 1% antibiotic-
antimycotic. The T-47D, SK-BR-3, ZR-75-1, and BT-549 cell lines were grown in
RPMI-1640 medium containing 10% FBS and 1% antibiotic-antimycotic. For SK-
BR-3 cells, medium additionally contained 1% sodium pyruvate and for BT-549, 1
μg/mL insulin. The BT-474 cells were grown in Hybri-Care medium containing
10% FBS, 1% sodium bicarbonate, and 1% antibiotic-antimycotic. The SUM44PE,
SUM52PE, and SUM159 cells were grown in Ham’s F12 medium containing 1%
antibiotic-antimycotic. For SUM159 cells, medium additionally contained 5% FBS,
1 μg/mL hydrocortisone, 5 μg/mL insulin, and 10 mM HEPES buffer. For the
SUM52PE cells, the medium additionally contained 10% FBS, 10 mM HEPES
buffer, 1 μg/mL hydrocortisone, and 5 μg/mL insulin. For SUM44PE cells, the
medium contained 2% FBS, 1 g/L bovine serum albumin, 5 mM ethanolamine, 10
mM HEPES buffer, 1 μg/mL hydrocortisone, 5 μg/mL insulin, 50 nM sodium
selenite, 5 μg/mL apo-Transferrin, and 10 nM triiodothyronine (T3). The MCF-
12A cells were cultured in 50% Ham’s F12 medium and 50% DMEM medium
containing 5% horse serum, 1% antibiotic-antimycotic and 20 ng/mL epidermal
growth factor (EGF), 10 μg/mL insulin, 500 ng/mL hydrocortisone and 100 ng/mL
of cholera toxin. For experiments involving non-genetically manipulated human
mammary epithelial cells (HuMECs) (Fig. 1f), human primary mammary epithelial
cells were purchased from ATCC (HMEC, PCS-600-010). These cells were grown
in Mammary Epithelial Cell Basal Medium (ATCC) supplemented with the
components of the Mammary Epithelial Cell Growth Kit (ATCC). For experiments
involving genetically manipulated (lentivirally transduced) HuMECs (Supple-
mentary Fig. 2a, c and d), the cell line hTERT-HME1 [ME16C] (ATCC CRL4010)
was utilized. These cells were grown in MEGMTM Mammary Epithelial Cell
Growth Medium BulletKitTM (Lonza), with supplements added according to the
manufacturers’ instructions.
The primary adult human dermal fibroblasts cells were purchased from ATCC
(HDFa, PCS-201-012, Supplementary Fig. 2c and Supplementary Data 6) and
grown in Fibroblast Basal Medium supplemented with Fibroblast Growth Kit-Low
Serum (ATCC) in accordance to manufacturers’ instructions. The 3T3-L1 cells
were grown in DMEM high glucose-pyruvate medium containing 10% FBS and 1%
antibiotic-antimycotic.
Immunohistochemistry (IHC). The IHC staining of AAMDC and RabGAP1L was
performed on a commercially available breast cancer tissue microarray (TMA)
(Biomax, #BR1503d) and it was automatized using the Ventana BenchMark
ULTRA IHC/ISH staining module available at the Fiona Stanley Hospital, Perth,
Australia. The slides were warmed to 75 °C for 4 min, deparaffinated, conditioned,
and treated with peroxidase inhibitor. The slides were then incubated for 32 min at
36 °C with α-AAMDC antibody (PTD015, Santa Cruz Biotechnology, 1:100) and α-
RabGAP1L antibody (Proteintech, 1:50). The slides were counter-stained with
Hematoxylin for 4 min. An ultraView Universal DAB Detection Kit (Ventana) was
used for chromogenic detection and visualization.
The IHC of MCF-7 xenograft tumors was performed on tissues harvested on
day 24, fixed in 4% paraformaldehyde, embedded in paraffin blocks, and cut into 5
μm sections. All of the sections for IHC were deparaffinized and hydrated with
graded concentrations of ethanol. The tumor sections were stained with α-Ki-67
(Cell Signaling Technology, 1:500), α−p-AKT S473 (Cell Signaling Technology,
1:100), total α−AKT (Cell Signaling Technology, 1:200), α-cMyc (Santa Cruz
Biotechnology, 1:200), α-MTHFD1L (Cell Signaling Technology, 1:200) or α-
AAMDC (Santa Cruz Biotechnology, 1:30) antibodies. Images were captured using
a Nikon Ti inverted microscope at ×40 magnification unless specified otherwise.
Immunocytochemistry (ICC). These cells were fixed with 4% paraformaldehyde in
phosphate-buffered saline (PBS), permeabilized in 0.025% Triton X-100, and
blocked with normal goat serum. Anti-AAMDC antibody (PTD015, Santa Cruz
Biotechnology, 1:100) in 10% normal goat serum was added to the cells and
incubated overnight at 4 °C. Cellular peroxidase activity was blocked with 0.3%
hydrogen peroxide in PBS. The cells were then incubated for 30 min at room
temperature with a biotinylated α-rabbit secondary antibody from the LSAB IHC
Kit (Rabbit IgG) (GeneCopoeia). Detection was performed with streptavidin-
horseradish peroxidase (HRP) for 30 min at room temperature, followed by 3,3-
diaminobenzidine (DAB) solution for signal development. Positive AAMDC cells
were detected under a light microscope Olympus IX71 (Singapore).
Fluorescence in situ hybridization. FISH was performed using commercially
available probes (Empire Genomics) labeled red (Red-dUTP 5-carboxyl-x-rhoda-
mine) for the AAMDC gene, and green for the pericentromeric region of chro-
mosome 11 (5-Fluorescein dUTP). After deparaffinization and rehydration, the
slides were soaked in pre-treatment solution (Histology FISH Accessory Kit, Dako)
and heated in a microwave oven for 10 min, followed by 17 min of pepsin digestion
(room temperature, RTU pepsin solution, Histology FISH Accessory Kit, Dako).
The slides were next dehydrated and 10 μL of probe working solution was applied
to each slide. After co-denaturation at 78 °C for 5 min, the slides were placed
overnight in a humid chamber at 37 °C. The fluorescence Mounting Medium
(Histology FISH Accessory Kit, Dako) was applied prior to visualization with a
fluorescence microscope (ZEISS, Germany). The FISH samples were analyzed
using Isis Fluorescence Imaging (MetaSystems, Germany). For each sample, at least
40 nuclei were counted. Cells with a ratio of gene-specific probe (AAMDC) to
control probe (pericentromeric region of chromosome 11) ≥2.0 were considered to
have amplification.
Molecular cloning. A fragment encoding residues 471–864 (N-3xHA-
RabGAP1LΔPTB(471) of full-length N-3xHA-RabGAP1L WT and a fragment
encoding residues 1–585 (N-3xHA-RabGAP1LΔTBC(585)) were amplified by PCR
from the pEZ-M06 N-3xHA-RabGAP1L WT plasmid (GeneCopoeia) and were
subcloned into the Pme1 and Not1 restriction sites of pEZ-M06 N-3xHA-
RabGAP1L WT (GeneCopoeia). For the N-3xHA-RabGAP1LΔTBC(585) amplifi-
cation, the primers used were: Forward 5′-CAGCCTCCGGACTCTAGC-3′ and
Reverse 5′-CTCCT
CCTCCTCCTCCTCCTCGCGGCCGCACTCGAGCTACACCAGAGTAGACAG
CCCTTT-3′. For the N-3xHA-RabGAP1LΔPTB(471) amplification, the primers
were: Forward 5′-GAGGAGGAGGAGGAGGAGGTTTAAACCGATTTTGGT
ATTTCAGCAG-3′ and Reverse 5′- GCTTATAATACGACTCACTATAGGG-3′,
as described in Supplementary Table 2. These transient expression vectors were
used in all the IPs (Fig. 8, Supplementary Fig. 6), intracellular localization studies
(Supplementary Fig. 8b), and BRET assays (Fig. 8g and Supplementary Fig. 8a).
The full-length RabGAP1L WT and the RabGAP1LΔPTB(471) inserts were
subcloned into the pLv105 lentiviral vector (Supplementary Fig. 9b–d). The
Fig. 6 AAMDC activates PI3K-AKT-mTOR signaling and promotes E2-independent tumor growth in vivo. a Activation of PI3K-AKT-mTOR signaling by
various ligands increases MTHFD1L expression, as determined by immunoblot (IB). Panels 1 and 2 (from left to right): Serum-starved SUM52PE subjected
to growth factor stimulation for 24 h with insulin (Ins, 300 μg/mL), fetal bovine serum (FBS, 20%), tumor necrosis factor α (TNFα, 50 ng/mL), and amino
acids (4 h). Panel 3: The estrogen receptor positive (ER+) cell line SUM44PE was estrogen-starved for 72 h and then stimulated with estrogen (E2, 1 nM)
for 24 h. Panel 4: Time-course of E2-mediated activation of the PI3K-AKT-mTOR-MTHFD1L axis in SUM44PE cells. Panel 5: Activation of PI3K-AKT-mTOR
upon lentiviral transduction of AAMDC cDNA in MCF-7 cells compared to empty vector (EV) and untransduced wild-type (WT) cells grown either under
starvation conditions (in the absence of serum, estrogen, or non-essential amino acids) or in complete medium for 24 h prior to immunoblotting with the
indicated antibodies (α). Source data are provided as a Source Data file. b Left: mRNA (top) and protein expression (bottom) levels in MCF-7 cells
lentivirally transduced either with AAMDC cDNA or EV grown under starvation conditions prior to their injection into nude mice. mRNA levels for the same
cells grown in complete medium are shown. Middle: mRNA expression of AAMDC in the extracted tumors (top) with representative images of the tumors
indicated (bottom), harvested at day 55. Right: Mean tumor volumes in nude mice injected with low growth factor (LGF) Matrigel® and with MCF-7 cells
transduced with either the EV or AAMDC cDNA. Mice were injected with 1 μg of estradiol valerate (+E2, top) or with vehicle control in the absence of
estrogen (-E2, bottom). The mean tumor volume of n= 8 mice is normalized to day 7 (left). Volume measurements of individual mice are plotted for the
selected time-points shown (right). Statistical significance is determined using a two-tailed unpaired t-test and presented as mean values ± SEM. For MCF-
7 cells and tumors: ***p= 0.0005, ****p < 0.0001. Multiple unpaired t-test for tumor volume +E2+ LGF: *p= 0.0214, left; *p= 0.0111, right. For tumor
volume −E2+ LGF (left plot): day 16 **p= 0.0086, day 20 *p= 0.0277, day 24 **p= 0.0052, day 27 *p= 0.0339, day 34 **p= 0.0026, day 38 *p=
0.0132, day 41 **p= 0.0042, day 45 ***p= 0.0009, day 48 ***p= 0.0002, day 52 ***p= 0.0004, day 55 ***p= 0.0003; (right plot): day 24 *p= 0.0175,
day 55 **p= 0.0011). Source data are provided as a Source Data file. c Immunohistochemistry (IHC) analysis of two representative tumors collected at day
55 for each condition. Tumor sections were stained with hematoxylin and eosin (H&E) or the antibodies indicated and the images quantified. The error bars
indicate the mean ± SEM. Statistical significance between empty vector (EV) and AAMDC cDNA conditions is determined by a two-tailed unpaired t-test
(***p= 0.0002, and ****p < 0.0001). n= 3 biologically independent animals.
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AAMDC-DAAE mutant was generated by site-directed mutagenesis of the PTB
binding consensus sequence, 20-NTTY-23 on pLv105-AAMDC (Supplementary
Fig. 9b).
For BRET assays, the AAMDC cDNA was N-terminally fused to the
bioluminescent donor RLuc8 (RLuc8-AAMDC), the Rab GTPases were N-
terminally fused to the Venus acceptor fluorophore (Venus-Rab), and RabGAP1L
(full-length and mutants, see above) were not fused with any reporter activity. The
Venus-HA-Rab7a expressing plasmid (in the pEYFP-C1 backbone, Clontech) was
kindly provided by Nevin Lambert (Georgia Regents University). The Venus-
Rab13, Venus-Rab22a, and Venus-Rab35 fusions were synthesized by GeneArt
(Thermo Fisher Scientific) and subcloned into a pcDNA3-Venus expressing
plasmid, while the RLuc8-AAMDC insert was synthesized by GeneArt and
subcloned into the pcDNA3-RLuc8 vector56.
Lentiviral production and transduction of breast cell lines. Lentiviral particles
expressing either the shRNAs or the cDNAs were generated by lentiviral trans-
duction of HEK293T cells transfected with 4.5 μg of either empty vector plasmids
(pLKO.1 or pLv105, GeneCopoeia, Supplementary Data 6), pLKO.1 expressing the
corresponding shRNA, or pLv105 expressing the selected cDNAs, and 1.54 μg of
pCI VSV-G Envelope plasmid, 2.88 μg of pMDLg/pRRE (GAG/POL), and 1.1 μg of
pRSV-Rev packaging plasmids (Addgene). The DNAs were mixed with 50 μL of
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Lipofectamine2000 transfection reagent (Thermo Fisher Scientific) in Opti-MEM
Reduced Serum Medium (Gibco). Four hours after transfection, the HEK293T
culture medium was replaced with a complete serum-containing medium. The
supernatants containing the viral particles were harvested 44, 51, and 68 h after the
medium replacement, and filtered through a 0.22 μm syringe filter (Millipore). The
Polybrene (Sigma) was added to the filtered viral supernatants at a final con-
centration of 8 μg/mL.
Transduction of shRNA- and cDNA-expressing lentiviruses. The host MCF-7,
T-47D, SUM52PE, HuMEC, and MDA-MB-134 cells were seeded in 10 cm dishes
and transduced with the lentiviral supernatants for a period of 8 h. The lentiviral
transductions were identically repeated three times by collecting the HEK293T
supernatants daily. Eight hours after the last transduction, the culture medium was
replaced with a fresh medium. Seventy-two hours later, transduced cells were
selected with 5 μg/mL of puromycin (Gibco) for the T-47D, 1.5 μg/mL for the
HuMEC, 1.25 μg/mL for the SUM52PE, and 1 μg/mL for the MCF-7 and the
MDA-MB-134 cell lines, respectively.
Double lentiviral transductions. For rescue experiments demonstrating the on-
target specificity of the AAMDC shRNA2, SUM52PE cells were initially transduced
with a first lentiviral vector, either pLKO.1 or the AAMDC shRNA2 (see lentiviral
transduction section above). Seventy-two hours post-transduction, the host cells
were selected with 1.25 μg/mL of puromycin. Immediately after selection, the cells
were transduced with the second lentivirus expressing either the empty vector
pLv105 or the AAMDC cDNA (Supplementary Fig. 1c). Similarly, double trans-
ductions were performed as in Supplementary Fig. 3a (transduction #1: either
pLKO.1 or the TSC2 shRNA1; transduction #2: either pLKO.1 or the AAMDC
shRNA2) and Supplemental Fig. 9c (transduction #1: either pLv105 or Rab-
GAP1LΔPTB; transduction #2: either pLKO.1 or the AAMDC shRNA2). These cell
lines were maintained in cell media containing 1.25 μg/mL of puromycin. The
efficacy of each individual consecutive transduction was validated by western
blotting.
Transient transfection assays. For the IP assays, HEK293T cells were transiently
transfected with various combinations of plasmid constructs expressing: N-Myc-
Rab7a, N-Myc-Rab13, N-Myc-Rab22a, N-Myc-Rab35 (in pEZ-M43, GeneCopoeia),
N-3xHA-RabGAP1L WT (in pEZ-M06, GeneCopoeia), and N-3xFLAG-AAMDC
(in the pcDNA3.1 (+) Zeo backbone, Invitrogen) (Fig. 8d–f and Supplementary
Fig. 6). In addition, HEK293T cells were transfected with plasmid constructs
expressing the mutants of RabGAP1L: N-3xHA-RabGAP1LΔPTB (RabGAP1L with
deletion of residues 1–471 defining the PTB domain) and N-3xHA-
RabGAP1LΔTBC (RabGAP1L with deletion of residues 585–815 comprising the
TBC domain) (in pEZ-M06, see molecular cloning, Supplementary Data 6).
For in vivo real-time fluorescence imaging (Supplementary Fig. 7a)
HEK293T cells were transiently transfected with N-eGFP-AAMDC (cloned in the
pcDNA3.1 (+) Zeo backbone, Invitrogen), N-eGFP-Rab7a, N-eGFP-RabGAP1L (in
pEZ-M29, GeneCopoeia), and mCherry-2xFYVEHrs construct (generously provided
by A/Prof Rohan Teasdale from The University of Queensland and generated by
subcloning 2xFYVEHrs from pEGFP-2xFYVEHrs into the pmCherry-C1 backbone,
Clontech). For IF assays on fixed cells (Supplementary Fig. 6f) HEK293T cells were
transfected with Ankyrin-B-2xHA (in the pEGFP-N1 backbone, Addgene) or N-
3xFLAG-AAMDC (in the pcDNA3.1 (+) Zeo backbone, Invitrogen).
To assess the intracellular localization of RabGAP1L and its mutants, and that
of Rab7a (Supplementary Fig. 8b), the HEK293T cells were co-transfected with: N-
Myc-Rab7a and full-length N-3xHA-RabGAP1L WT or its deletion mutants N-
3xHA-RabGAP1LΔPTB or N-3xHA-RabGAP1LΔTBC.
The transfections were performed using Lipofectamine2000 reagent (Thermo
Fisher Scientific) according to the manufacturer’s protocol. For the IP experiments,
HEK293T cells were transfected with 10 μg of plasmid DNA, and for the IF
localization experiments, the cells were seeded onto 13 mm glass coverslips pre-
treated with poly-L-lysine prior to transfection with 0.66 μg of plasmid DNA. The
transfection media was replaced by complete serum-containing media 4 h after
transfection. For the IP experiments, total protein extract was collected 48 h post-
transfection, while for IF, the cells were fixed in 4% paraformaldehyde 24 h post-
transfection.
For the BRET assays, the HEK293FT cells were transfected with various
combinations of Venus-HA-Rab7a, Venus-Rab13, Venus-Rab22a and Venus-
Rab35, RLuc8-AAMDC, RabGAP1L WT, RabGAP1LΔPTB, and RabGAP1LΔTBC
(Fig. 8g and Supplementary Fig. 8a). The transfections were carried out using
FuGENE 6 transfection reagent (Promega). The cells were harvested with 0.05%
trypsin-EDTA 24 h after transfection and seeded into poly-L-lysine (Sigma
Aldrich)-coated white 96-well plates in phenol red-free DMEM containing 25 mM
HEPES, 0.3 mg/mL glutamine, 100 IU/mL penicillin, and 100 μg/mL streptomycin
supplemented with 5% FCS.
Quantitative real-time PCR (RT-qPCR). Total RNA was extracted from tissue
and transfected and transduced cells using QIAzol Lysis Reagent (Qiagen). The
tumor tissue was homogenized at 30 Hz, 30 s cycles using a Qiagen TissueLyser II.
cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). Relative quantification of transcript expression was obtained
by RT-qPCR using TaqMan probes in the ViiATM 7 RT-PCR machine (Applied
Biosystems). The mRNA levels of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), Peptidylprolyl Isomerase A (PPIA), and Glucuronidase Beta (GUSB) were
used for normalization. The AAMDC mRNA levels in a panel of breast cancer cell
lines were expressed as fold change relative to that of MCF-12A cells after nor-
malization with the housekeeping genes.
Ki-67 proliferation and cleaved caspase-3 marker detection by immuno-
fluorescence. The untransduced T-47D, MDA-MB-134, HuMEC, and SUM52PE
cells or the cells lentivirally transduced with the empty vector pLKO.1 or with
AAMDC and MTHFD1L shRNAs were seeded onto 13 mm glass coverslips pre-
treated with poly-L-lysine (Sigma-Aldrich). The adhered cells were fixed with 4%
paraformaldehyde for 20 min, washed twice with PBS, blocked with 5% normal
goat serum for 1 h, and separately incubated with α-Ki-67 mouse monoclonal
primary antibody (Cell Signaling Technology, 1:500) and with α-cleaved caspase-3
(Cell Signaling Technology, 1:500) in antibody diluent (1% BSA and 0.3% Triton
X-100 in PBS) overnight and further incubated with a goat α-mouse secondary
Alexa Fluor 488-conjugated antibody (Thermo Fisher Scientific, 1:500) and goat α-
rabbit secondary Alexa Fluor 488-conjugated antibody (Thermo Fisher Scientific,
1:500), respectively. The percentage of Ki-67 and cleaved caspase-3 positive cells
versus total cells (Hoechst 33258, 1:5000) was assessed in at least 9 fields of view.
Data were normalized to empty vector (EV) transduced cells.
Immunofluorescence assays. Immunofluorescence (IF) experiments for assessing
the cellular localization of endogenous AAMDC and Rab-GTPase activating pro-
tein 1 like (RabGAP1L) proteins were performed in selected luminal breast cancer
cell lines (Fig. 8a). The IF experiments for assessing the localization of
phosphorylated-mammalian target of rapamycin serine 2448 (p-mTOR S2448),
tuberous sclerosis complex 2 (TSC2), p110α with lysosome-associated membrane
Fig. 7 Sensitization of luminal IntClust2 cell lines expressing AAMDC by co-treatment with PI3K-AKT-mTORC1 blockers in combination with
tamoxifen. a Pharmacological blockade of PI3K-AKT-mTOR leads to downregulation of MTHFD1L expression in estrogen receptor positive (ER+)
intercluster 2 (IntClust2) breast cancer cell lines (SUM44PE and MDA-MB-134) treated with tamoxifen (Tam, 5 μM) in combination with dactolisib or
everolimus (24 h, at the concentrations indicated in the blots). Source data are provided as a Source Data file. b–d Dose-dependent changes in cell viability
in the ER+ breast cancer cell lines MDA-MB-134 (b), SUM44PE (c), and T-47D (d) treated with dactolisib (Dacto., top, blue) or everolimus (Evero.,
bottom, blue), with tamoxifen (Tam., red) and as combinations (green). Data are presented as mean values ± SD. n= 3 biologically independent
experiments. Viability is determined using a luminescence assay (CellTiter-Glo®) after 72 h post-treatment. e Tamoxifen and selected inhibitors of the
PI3K-AKT-mTOR pathway exhibit synergistic pharmacological interactions in inhibiting tumor cell viability. Plots indicating the combination index (CI) for
tamoxifen with dactolisib (purple) and tamoxifen with everolimus (cyan) in MDA-MB-134 (left), SUM44PE (middle), and T-47D (right) cells. CI <
1 synergistic, CI= 1 additive, and CI > 1 antagonistic. The CI is calculated from the average of three independent cell viability assays by the CI index method.
Fraction affected is the fraction of non-viable cells. f Dose-dependent changes in cell viability in the MCF-7 cell line stably overexpressing AAMDC cDNA
compared to empty vector (EV) treated with dactolisib, everolimus, and docetaxel. Statistical significance is determined for biological triplicates and
presented as mean values ± SD and p-values are determined by multiple unpaired t-tests. For dactolisib, from left to right: **p= 0.0007, **p= 0.0013, **p
= 0.0016, ***p < 0.0001, ***p < 0.0001; for everolimus, from left to right: *p= 0.0062, *p= 0.0053, *p= 0.0066. Bottom right: Relative AAMDC mRNA
expression in a panel of ER+ breast cancer cell lines normalized to the non-tumorigenic epithelial line MCF-12A, as assessed by qRT-PCR. Data presented
as mean values ± SD and p-values are determined by two-tailed unpaired t-test with Welch’s correction (*p= 0.0308, **p= 0.0012, ***p= 0.0001).
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protein 2 (LAMP2), early endosome antigen 1 (EEA1) (Supplementary Fig. 3b),
and FGFR2 (Supplementary Fig. 7b) were performed in SUM52PE cells transduced
with either empty vector (pLKO.1) or AAMDC sh2. The cells were seeded over-
night in 13 mm glass coverslips pre-treated with poly-L-lysine (Sigma-Aldrich).
Subsequently, the cells were fixed with 4% paraformaldehyde, blocked with 5%
normal goat serum, and incubated overnight at 4 °C with the primary antibodies α-
AAMDC mouse monoclonal (Abcam, 1:30), α-RabGAP1L rabbit polyclonal
(Proteintech, 1:50), α-phospho-mTOR (Ser2448) rabbit monoclonal (Cell Signaling
Technology, 1:50), α-TSC2 rabbit monoclonal (Cell Signaling Technology, 1:800),
α-PI3 Kinase p110α rabbit monoclonal (Cell Signaling Technology, 1:100), α-
LAMP2 mouse monoclonal (Santa Cruz Biotechnology, 1:100), α-EEA1 rabbit
polyclonal (Cell Signaling Technology, 1:100), and α-FGFR2 rabbit monoclonal
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(Cell Signaling Technology, 1:100), diluted in antibody diluent (1% BSA and 0.3%
Triton X-100 in PBS). The F-actin staining was performed using Alexa Fluor™ 488
Phalloidin (Thermo Fisher Scientific, 1:500, Fig. 2e and Supplementary Fig. 9d).
For IF experiments involving transiently transfected HEK293T cells, the
following primary antibodies were used: α-Myc Tag rabbit monoclonal (Cell
Signaling Technology, 1:200), α-HA Tag antibody rat monoclonal (Novus
Biologicals, 1:100), and α-FLAG (DYKDDDDK) Tag (9A3) mouse monoclonal
(Cell Signaling Technology, 1:1600) (Supplementary Fig. 6f and 8b). The cells were
then incubated for 1 h at room temperature with the following secondary
antibodies: goat α-mouse or α-rabbit 488-conjugated antibody, goat α-mouse or α-
rabbit 594-conjugated antibody, and goat α-rat 647-conjugated antibody (Thermo
Fisher Scientific, 1:500). The cells were incubated with Hoechst 33258 (Sigma-
Aldrich, 1:5000) for nuclei staining for 15 min. The coverslips were mounted onto
slides and imaged using a Nikon A1Si inverted confocal microscope.
For the live cell imaging (Supplementary Fig. 7a), HEK293T cells transiently
cotransfected with mCherry-2xFYVE and either eGFP-Rab7a, eGFP-RabGAP1L or
eGFP-AAMDC, were grown on glass-bottom culture dishes (35 mm petri dish, 10
mm microwell with no. 1.5 coverglass, MatTek Corporation) and imaged by time-
lapse fluorescence confocal microscopy using an inverted 100× (CFI Plan Apo
Lambda Oil, N.A. 1.45) objective lens under controlled atmospheric conditions (37
°C and 5% CO2/Air) in a Tokai Hit Stage Top incubator (INUG2E-TIZ,
Fujinomiya-shi, Shizuoka-ken, Japan). Frames were captured continuously for 5
min using NIS-C Elements AR (Version 4.13) software and processed using
ImageJ.
Anchorage-independent colony formation assays. Anchorage-independent
growth was assessed with soft agar colony formation assays. The HuMEC, HDFa,
T-47D, SUM52PE, or MDA-MB-134 cells were seeded in six-well plates, in 0.48%
agarose in complete medium (Sea Plaque Low-Melting Agarose, Lonza), over a
solid layer of 0.8% agarose in complete medium. Five-hundred microliters of
complete growth medium were added to each well and replaced every 3 days. The
colonies were allowed to grow for 3–4 weeks. The colonies were stained with
methylthiazolyldiphenyl-tetrazolium bromide (MTT) (Sigma) at 0.5 mg/mL in
complete media, washed in PBS and counted by Leika light microscope in 12
random fields of view.
Induction of the PI3K-AKT-mTOR pathway. For cell signaling studies, SUM52PE
cells were serum- and insulin-starved overnight and then treated with insulin (Ins,
300 μg/mL), 20% FBS, or tumor necrosis factor α (TNFα, 50 ng/mL) for 24 h or left
untreated before being lysed for immunoblotting. For amino acid induction,
SUM52PE cells were serum- and insulin-starved overnight and then maintained in
Dulbecco’s phosphate-buffered saline (DPBS) for 1.5 h to remove the amino acids
from the cell medium, followed by induction by adding 2× solution containing
non-essential (100× stock) and essential (50× stock) amino acids (Gibco). Four
hours post-induction, the cells were lysed for immunoblotting. Cells maintained in
DPBS were used as mock controls.
For estrogen induction, SUM44PE or T-47D cells were first cultured for 72 h in
estrogen-free medium (for SUM44PE: Ham’s F12 medium without phenol red,
supplemented with the following agents (at their final concentrations): 2%
charcoal-stripped FBS, 1 g/L bovine serum albumin, 5 mM ethanolamine, 10 mM
HEPES buffer, 1 μg/mL hydrocortisone, 5 μg/mL insulin, 50 nM sodium selenite, 5
μg/mL apo-Transferrin, 10 nM triiodo-thyronine (T3), and 1% antibiotic-
antimycotic; for T-47D: RPMI-1640 medium without phenol red, supplemented
with 10% charcoal-stripped FBS and 1% antibiotic-antimycotic). The cells were
then seeded in estrogen-free medium, incubated overnight, and estrogen (Sigma-
Aldrich) (1 nM) was added for 15, 30, 60, 120 min, 7 h, and 24 h (SUM44PE) or 24
h (T-47D) before lysis for immunoblotting.
Bioluminescence energy resonance transfer (BRET) assay. Forty-eight hours
post-transfection of the HEK293FT cells with the corresponding plasmids (see
transient transfection assays), the DMEM complete media was replaced with 5 μM
coelenterazine h (Promega) in calcium- and magnesium-free Hank’s Balanced Salt
Solution (HBSS). The BRET measurements were immediately taken at 37 °C using
a LUMIstar Omega plate reader (BMG Labtech Mornington, Vic, Australia). Fil-
tered light emissions were simultaneously measured at 460–490 nm for RLuc8 and
520–550 nm for Venus. The BRET ratio was calculated by subtracting the ratio of
520–550 nm emission and the 460–490 nm emission57,58.
Induction of 3T3-L1 pre-adipocytes into mature adipocytes. The 3T3-L1 mouse
embryonic fibroblasts were treated with complete medium supplemented with
MDI reagents (2 μM insulin, 1 μM dexamethasone, 0.5 μM 3-isobutyl-1-methyl-
xanthine) to induce adipocytic differentiation for 48 h. The medium was then
replaced with a complete medium supplemented with 2 μM insulin for a further 48
h before Oil Red O staining.
Oil Red O staining of neutral lipids. For the quantitative assessment of neutral
lipid formation, the HuMEC or SUM52PE cells lentivirally transduced with the
AAMDC cDNA or the AAMDC shRNA2 and controls (Supplementary Fig. 2d)
were washed in PBS, fixed with 4% paraformaldehyde for 30 min, washed in dis-
tilled water, and briefly incubated in 40% isopropanol. Following the equilibration,
the cells were stained with 40% Oil Red O solution for 20 min and counterstained
with hematoxylin. Coverslips were mounted onto slides and imaged with a Nikon
Ti inverted microscope. Images were collected using NIS-Elements AR (Version
4.13) software and processed using ImageJ.
Migration assays. Migration assays were performed similarly to Moses et al.59.
Transwell polycarbonate membrane filter inserts with 8 μm pore size (Cell Biolabs)
were rehydrated and placed in 24-well tissue culture plates. MCF-7, T-47D, and
SUM52PE cells were transduced with either AAMDC shRNAs or empty vector
pLKO.1. The cells were serum-deprived overnight and added to the top chambers
of the transwells. Ten percent serum-containing media was added to bottom
chambers. The plates were next incubated at 37 °C for 24 h and then the culture
media was aspirated. To visualize the migratory cells, the inserts were incubated
with 400 μL cell stain solution (Cell Biolabs) for 10 min and pictures were captured
using a cell culture inverted Leika light microscope to quantitate the number of
cells that had passed through the porous membrane in 12 random fields. Results
were expressed as average values relative to the empty vector pLKO.1 cells.
In vivo tumor growth assay. For the generation of the AAMDC shRNA KD
xenografts, 5 × 106 T-47D cells stably transduced with either pLKO.1 lentiviral
empty vector or AAMDC sh2 were injected subcutaneously into the right flank of
5-week-old female BALB/cJ Foxn1/Arc (Nude) mice. Prior to inoculation, the cells
were resuspended in 100 μL of a 1:1 solution of Ham’s F12 medium and BD
Matrigel® High Concentration (BD Bioscience). One microgram of estradiol
valerate dissolved in 50 μL of peanut oil (Sigma-Aldrich) was injected sub-
cutaneously in the proximity of the tumor every 4 days to allow the estrogen-
dependent T-47D cells to proliferate. The widths and the lengths of the tumors
Fig. 8 AAMDC interacts with the GTPase activating protein RabGAP1L. a Colocalization of endogenous AAMDC and RabGAP1L proteins in luminal
breast cancer cells assessed by immunofluorescence (IF). Hoechst 33258-stained nuclei (blue), α-AAMDC antibody (green), and α-RabGAP1L antibody
(red). Arrows indicate regions of strong signal overlap. b Localization of AAMDC and RabGAP1L in adjacent representative sections of normal breast, and
in selected estrogen receptor negative (ER−) or invasive ductal carcinoma (IDC) breast cancer specimens assessed by immunohistochemistry (IHC). c
Superposition of the crystal structure of bacterial (1IHN, cyan, https://doi.org/10.2210/pdb1IHN/pdb)11,54 and human (2AB1, orange, https://doi.org/
10.2210/pdb2AB1/pdb)55,74 AAMDC proteins (left) and the Phyre2 (v2.0) homology model of human RabGAP1L. The phosphotyrosine-binding (PTB)
domain is shown in red and the C-terminal Tre-2/Bub2/CdC16 (TBC) Rab-binding domain in violet (right). d–f Interaction between AAMDC, RabGAP1L,
and Rab7a by immunoprecipitation (IP) in HEK293T cells transiently transfected with full-length (d) or deletion mutants (e–f) of the tagged cDNAs: HA-
RabGAP1L, FLAG-AAMDC, and Myc-Rab7a. The IPs were immunoblotted with an α-HA antibody to detect HA-RabGAP1L (98 kDa) or α-FLAG to detect
FLAG-AAMDC (17 kDa). Deletion of the PTB domain is indicated by HA-RabGAP1LΔPTB(471) (48 kDa) (e), and deletion of the Rab-binding TBC domain
by HA-RabGAP1LΔTBC(585) (64 kDa) (f); α-IgG-conjugated beads and beads only are used as a control. g Bioluminescence resonance energy transfer
(BRET) assays in HEK293FT cells transiently overexpressing Venus-HA-Rab7a or Venus-Rab22a, RLuc8-AAMDC, full-length RabGAP1L, RabGAP1LΔPTB, or
RabGAP1LΔTBC. Control cells (Ctrl) are transfected with Venus-Rab and RLuc8-AAMDC only. The BRET ratio values are normalized to the respective
controls. The individual values for n= 4 biological replicates (Rab7a) and for n= 3 biological replicates (Rab22a) are shown as mean values ± SEM, and
statistical significance is determined using Brown-Forsythe and Welch ANOVA tests with Dunnett’s T3 multiple comparison test (Rab7a: **p= 0.0096 for
Ctrl vs. RabGAP1L WT, **p= 0.0069 for RabGAP1L WT vs. RabGAP1LΔPTB, and not significant (ns) for RabGAP1L WT vs. RabGAP1LΔTBC and for
RabGAP1LΔPTB vs. RabGAP1LΔTBC; Rab22a: **p= 0.0024 for Ctrl vs. RabGAP1L WT, **p= 0.0045 for RabGAP1L WT vs. RabGAP1LΔPTB, **p= 0.0020
for RabGAP1L WT vs. RabGAP1LΔTBC, and ns for RabGAP1LΔPTB vs. RabGAP1LΔTBC).
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were measured every 3–4 days using digital calipers for 14 days. Tumor volumes
were calculated using the modified ellipsoid formula; V= [(width2) × ½ × length].
Animals bearing tumors >800 mm3 were humanely sacrificed.
For the AAMDC cDNA overexpression in xenografts, 1 × 106 MCF-7 cells
stably transduced with either pLv105 lentiviral empty vector or AAMDC cDNA
were injected subcutaneously into the right flank of 5-week-old female BALB/cJ
Foxn1/Arc mice. Twenty-four hours prior to inoculation, the cells were placed into
minimal essential medium (MEM) and then resuspended in 100 μL of a
1:1 solution of MEM and Matrigel® Growth Factor Reduced (GFR) phenol red-free
(Corning) for injection. +E2 mice were given injections of estradiol valerate every
3–4 days. The mice were monitored and the tumor sizes were measured as
described above.
RNA sequencing (RNA-seq). Total RNA was extracted from SUM52PE cells
lentivirally transduced with the empty vector pLKO.1 and AAMDC sh2 according
to the instructions of the RNeasy Mini Kit (Qiagen). For the drug-treated samples,
SUM52PE cells were treated twice every 36 h with dactolisib, everolimus, or
AZD8055 (Selleck Chem, 100 nM) or buparlisib (Selleck Chem, 1000 nM), or
vehicle control. After 72 h, total RNA was extracted from the cells using QIAzol
Lysis Reagent (Qiagen) and the samples were DNase treated with the TURBO
DNA-free™ Kit (Thermo Fisher Scientific).
Eluted RNA samples were sequenced using the HiSeq 2500 System at the
Australian Genome Research Facility (AGRF) in Melbourne, with Illumina’s
TruSeq stranded mRNA sample preparation protocol used for library preparation.
The RNA sequencing data have been deposited in the Gene Expression Omnibus
public database under accession numbers GSE92893 and GSE123740.
Western blotting. For protein extraction, the cells were washed twice with PBS
and lysed in ice-cold Cell Lysis Buffer (Cell Signaling Technology) containing 1
mM phenylmethylsulfonyl fluoride (PMSF) then sonicated for 5 s at 10 mA. From
each sample, 15 μg protein was resolved by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes (BioRad).
Immunoreactivity was determined with primary antibodies (1:1000) as described in
Supplementary Data 6, except for mouse monoclonal α-AAMDC (Abcam, 1:500),
and secondary goat α-rabbit or α-mouse antibodies (1:10,000). The membranes
were visualized by NovexTM ECL HRP Chemiluminescent Substrate Reagent Kit
(Thermo Fisher Scientific) or Luminata crescendo (MilliporeSigma™) using the
ChemiDocTM Imaging System (Bio-Rad).
IP experiments. The HEK293T cells were co-transfected for 48 h with various
combinations of plasmids expressing the following tagged constructs: Myc-Rab7a,
Myc-Rab13, Myc-Rab22a, Myc-Rab35, FLAG-AAMDC, HA-RabGAP1L, HA-
RabGAP1LΔPTB, HA-RabGAP1LΔTBC, and Ankyrin-B-HA (see transient trans-
fection assays, Supplementary Data 6). The cells were harvested and lysed by
sonication in lysis buffer (Cell Signaling Technology) containing 1 mM PMSF and
then pelleted by centrifugation. Two-hundred microliters of cell lysate were col-
lected for each IP. Unconjugated beads and beads conjugated with IgG were uti-
lized for controls; beads conjugated with Myc-Tag (Cell Signaling Technology), α-
FLAG, and α-HA were used to immobilize the Myc-tagged Rab proteins, FLAG-
tagged AAMDC, and HA-tagged RabGAP1L (full length and mutant proteins),
respectively. Dynabeads™ Protein G (Thermo Fisher Scientific) were conjugated by
incubation with PBST (beads only), IgG antibody (SCBT), or α-HA antibody
(BioLegend) for 10 min at room temperature. Two-hundred microliters of lysate
were incubated with 30 μL of beads for 10 min at room temperature with rotation
for IgG, α-HA, and α-MYC IPs, and overnight at 4 °C for FLAG-conjugated beads.
The beads were washed three times with TBST or TBS, and bound protein was
eluted in 50 μL of SDS-PAGE buffer and separated directly by SDS-PAGE.
Comprehensive metabolomics. Metabolomics was performed using liquid
chromatography-mass spectrometry (LC-MS). Cultured cells (1.5 × 106 cells/sam-
ple) were washed three times with PBS, pelleted by centrifugation, and then stored
at −80 °C. Cell pellets were resuspended in 100 μL of ice-cold 80:20 methanol:water
and lysed by three freeze-thaw cycles. An additional 300 μL of ice-cold 80:20
methanol:water was added, and the samples were sonicated and centrifuged at
14,000 × g for 10 min at 4 °C. The supernatants (375 μL) were dried using a vacuum
concentrator. The samples were re-suspended in 50 μL of 80:20 methanol:water
and then sonicated, vortexed, and centrifuged at 14,000 × g for 10 min at 4 °C. An
injection volume of 2.5 μL, which contained metabolic material from ~75,000 cells,
was used for all of the cell samples. LC-MS/MS-based metabolomics analysis was
performed using a Thermo Q Exactive Orbitrap mass spectrometer coupled to a
Thermo Vanquish UPLC system. Chromatographic separation of metabolites was
achieved using a Millipore (Sequant) Zic-pHILIC 2.1 × 150 mm 5 μm column
maintained at 25 °C. The collected data was imported into mzMine 2.20 software
suite for analysis. Pure standards were used for the identification of metabolites
through manual inspection of spectral peaks and matching of retention time and
MS1 accurate mass, with confirmation of the identification through comparison to
MS/MS fragmentation patterns.
Yeast two-hybrid screenings. The yeast two-hybrid screenings were carried out
by Hybrigenics Services, S.A.S., Paris, France. The Homo sapiens AAMDC coding
sequence (https://www.ncbi.nlm.nih.gov/nuccore/34328078) was cloned into the
pB27 vector as a C-terminal fusion with the LexA DNA-binding domain (N-LexA-
AAMDC-C), and into the pB66 backbone as a C-terminal fusion with the DNA-
binding domain of Gal4 (N-Gal4-AAMDC-C). These constructs were utilized as
baits for the screening of a human cDNA library generated by random priming
from the T-47D, MDA-MB-468, MCF-7, and BT-20 breast cancer cell lines. The
library was next cloned into the pP6 vector.
Eighty-five million clones (eightfold the complexity of the library) and 68
million clones (sixfold the complexity of the library) were screened with the LexA
and the Gal4 constructs, respectively. A mating approach with the YHGX13 (Y187
ade2–101::loxP-kanMX-loxP, matα) and the L40Δgal4 (mata) yeast strains were
employed for the LexA screenings. Similarly, a mating method with the HGX13
(Y187 ade2–101::loxP-kanMX-loxP, matα) and the CG1945 (mata) yeast strains
was performed for the Gal4 screenings. A total of 16 His+ colonies were selected
on a medium without tryptophan, leucine, and histidine, while 53 His+ colonies
were selected on a medium lacking tryptophan, leucine, and histidine, respectively.
The positive clones (prey fragments) were PCR-amplified and sequenced at their 5′
and 3′ junctions (Supplementary Data 5). The resulting sequences were used to
identify the corresponding interacting proteins in the GenBank database (NCBI) by
a fully automated procedure. A confidence score (PBS, for Predicted Biological
Score) was attributed to each interaction60.
Chromatin immunoprecipitation (ChIP). ChIP experiments were performed in
biological triplicates. For each ChIP sample, SUM52 cells were seeded in 1 × 15 cm2
tissue culture plate with a final confluence of >80% and treated with either PBS
(vehicle) or 100 nM dactolisib. In addition, SUM52 cells transduced with empty
vector pLKO.1 or AAMDC shRNA2 were also seeded in the same conditions. These
cells were fixed for 10 min at room temperature with 20 mL complete media
containing 1% paraformaldehyde (Thermo-Fisher). One mL of 2.5 M glycine was
added to each plate to quench unreacted formaldehyde. The media was aspirated
and the fixed cells washed twice with 1× ice-cold PBS containing 1 mM PMSF. The
cells were aseptically scraped using cell scrapers (Sarstedt) and pelleted at 1150 × g
for 4 min at 4 °C. The cell pellets were washed twice in 1× ice-cold phosphate-
buffered saline (PBS) and resuspended in 1 mL sodium dodecyl sulfate (SDS) Lysis
Buffer (1% SDS, 10 mM ethylenediaminetetraacetic acid (EDTA), 50 mM Tris-Cl
pH 8.1 in sterile milliQ water). The samples were sonicated using a Covaris M220
instrument at 4 °C to fragment chromatin into 200–1500 bp segments. Following
sonication, equal amounts of ChIP dilution buffer (0.1% SDS, 1% Triton X-100, 2
mM EDTA, 20 mM Tris-Cl pH 8.1, 150 mM NaCL in sterile milliQ water) was
added to each sample. The insoluble components were removed by centrifugation
at 15,500 × g for 10 min at 4 °C. Sheared chromatin was conjugated with α-c-MYC-
antibody (Cell Signaling Technology, 1:50) and α-ATF4-antibody (Cell Signaling
Technology, 1:100). The samples were incubated with the corresponding antibodies
for 4 h on a rotator at 4 °C and no antibody samples were investigated as negative
controls. Per each ChIP reaction, 200 μL Dynabeads™ Protein G (Invitrogen) were
washed twice with ChIP dilution buffer and added to the sheared chromatin-
antibody samples. The conjugated samples and beads were incubated on a rotator
overnight at 4 °C. After incubation, beads were washed for 5 min with a single wash
of the following ice-cold buffers: low salt wash buffer (0.1% deoxycholate, 1%
Triton X-100, 1 mM EDTA, 50 mM HEPES pH 7.5, 150 mM NaCL in sterile milliQ
water), high salt wash buffer (0.1% deoxycholate, 1% Triton X-100, 1 mM EDTA,
50 mM HEPES pH 7.5, 500 mM NaCl) and LiCl wash buffer (250 mM LiCl, 0.5%
NP40, 0.5% deoxycholate, 1 mM EDTA, 10 mM Tris-Cl pH 8.1). Beads were
washed twice with TE Buffer (Invitrogen, pH 8.0) for 5 min for each wash. The
immunoprecipitated chromatin was eluted from beads by incubation for 1 h at 60 °
C in SDS elution buffer (1% SDS, 10 mM EDTA, 50 mM Tris-Cl pH 8.1) followed
by a reverse cross-link incubation overnight at 70 °C. Samples were treated with
RNase A and Proteinase K, and the DNA was purified using the phenol-
chloroform phase separation DNA extraction method. The immunoprecipitated
DNA was quantified using the Qubit 4 Fluorometer (Invitrogen).
Chromatin immunoprecipitation coupled with quantitative PCR (ChIP-qPCR).
The ChIP-qPCR method enabled the amplification of the genomic regions con-
taining TF binding sites in the proximal promoter of MTHFD1L and ASNS. The
qPCR was performed with the QuantiFast SYBR Green PCR master mix (Qiagen)
using a ViiA 7 Real-Time PCR System (Applied Biosystems). The amplification of
exon 6 of the Actin Beta (ACTB) gene having no TF binding sites was assessed as
control. Sequences of the promoter-specific oligonucleotide primers (Integrated
DNA Technologies) used in this study were MTHFD1L Forward 5′-GTTTAGGG
GCGATTTTGTGACCAC-3′, MTHFD1L Reverse 5′-TGATTGGTTCCAG
GGCCCCTC-3′, ASNS Forward 5′-AGTCCTGCTCCGCCC-3′, and ASNS Reverse
5′-GCACGCGAGGAGGATGC-3′. Amplification of exon 6 of ACTB was per-
formed with the following primers: hActB_ex6_Forward 5′-GATGAGATTG
GCATGGCTTT-3′ and hActB_ex6_Reverse 5′-CACCTTCACCGTTCCAGTTT-3′
(Supplementary Table 2). The ChIP qPCR data were expressed as fold-increase of
signal at the proximal promoters of MTHFD1L and ASNS normalized to the signal
at the ACTB promoter and calculated for validated peak enrichment from three
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biological replicates of 100 nM dactolisib and sh2 against AAMDC vs. vehicle
control and pLKO.1, respectively.
Drug treatments and cell viability assays. For assessment of PI3K-AKT-mTOR
pathway activity (Fig. 4b), the SUM52PE cells were treated with four different drug
regimes: (1) dactolisib; (2) AZD8055; (3) everolimus at concentrations of 0, 1, 10,
and 100 nM; and (4) buparlisib at concentrations of 0, 1, 10, 100, 500, and 1000 nM
for a period of 24 h. For assessment of drug combinations on PI3K-AKT-mTOR
pathway activity (Fig. 7a), the SUM44PE and MDA-MB-134 cells were treated with
combinations of: (1) dactolisib; (2) everolimus (10 and 50 nM) and tamoxifen (5
μM) for a period of 24 h. Single drug treatments were used as controls. The cells
were harvested in Cell Lysis Buffer (Cell Signaling Technology) for subsequent
immunoblotting.
For insulin rescue experiments (Supplementary Fig. 3c), SUM52PE cells
transduced with either empty vector (EV) or AAMDC shRNAs as well as
untransduced cells (WT) were insulin starved overnight. Cells were vehicle treated
or stimulated with insulin (300 μg/mL) for 7 h and then harvested in Cell Lysis
Buffer.
For cell viability assays (Fig. 7b–e), the MDA-MB-134, SUM44PE, and T-47D
cell lines were treated with single agents: (1) tamoxifen (0–20 μM); (2) dactolisib
(0–200 nM); and (3) everolimus (0–200 nM); or in combination treatments of
dactolisib or everolimus with different doses of tamoxifen. Cells were treated for a
period of 72 h and processed with CellTiter-Glo® 2.0 luminescence assay protocol
(Promega) to determine cell viability.
To investigate the influence of the AAMDC cDNA on the drug responses of
MCF-7 cells, these cells were stably transduced with empty vector (EV) or
overexpressing the AAMDC cDNA and treated with either: (1) dactolisib (0–200
nM); (2) everolimus (0–200 nM); and (3) docetaxel (1–100 nM) for 72 h and
processed by CellTiter-Glo® 2.0 luminescence assay protocol (Promega).
Luminescence was measured using the EnVision® Multilabel Plate Reader
(PerkinElmer). The luciferase measurements were normalized to the vehicle
condition (untreated).
Quantification and statistical analysis. The AAMDC mRNA expression, Ki-67
immunofluorescence61, anchorage-independent cell growth, cell migration, cleaved
caspase immunofluorescence, and dose-dependent changes in cell viability were
normalized to the empty vector (EV). The relative AAMDC mRNA expression in a
panel of ER+ breast cancer cell lines was normalized to the non-tumorigenic
epithelial line MCF-12A. Unless otherwise indicated in the figure, the experiments
were performed on at least three independent biological replicates. For the in vivo
tumorigenicity of AAMDC sh2 KD, statistical significance was determined with n
= 8 mice/group, while for MCF-7 AAMDC cDNA, n= 7 mice were analyzed for
the +E2 EV group and n= 8 mice for other groups until day 24, when one mouse
from each group was culled. The statistical analyses were performed using Prism
7 software for Mac OS X. For the analysis of differentially regulated metabolites by
LC-MS, the experiments were performed on three independent biological repli-
cates, and statistical significance was determined by an unpaired t-test. Metabolites
were considered to be significantly regulated when the −2 < log2FC was <2 and the
p-value was <0.05 (FC= fold change). For the RNA-seq data shown in Fig. 3,
sequenced reads were aligned to the human (hg19) genome using TopHat
(v2.0.14)62, and expression at the gene level (FPKM values) was estimated and
normalized by Cufflinks (v2.2.1), Cuffmerge (v1.0.0), and Cuffnorm (v2.2.1).
Differential gene expression analysis was performed using Cuffdiff (v2.2.1), with
significant changes in gene expression determined using a q-value < 0.05 in three
biological replicates. For the RNA-seq data shown in Fig. 5, the sequenced reads
underwent pseudo-alignment against the GRCh38 (Ensembl 89) reference genome
and quantification using Salmon (v0.8.2)63. The data were imported into R (v3.5)
using the Bioconductor package tximport64 and collapsed to the gene-level for
differential expression analysis using DESeq2 (v1.24.0)65. The results were visua-
lized with python (v3.6) using the matplotlib66, SciPy (v1.3.0)67, NumPy (v1.16.4
+mkl)68, and pandas (v0.24.2) packages69. All quantifications were done in at least
3–6 biological replicates and the mean ± SD is indicated in all of the quantifica-
tions. The Oil Red O staining experiments were performed with two independent
biological replicates. The % neutral lipids were visually quantified relative to the
total number of cells. The statistical analyses were conducted using Prism 8 soft-
ware, with significance determined using an unpaired t-test.
Software and algorithms. The image processing and quantification of the data
were performed with NIS-Elements AR (Version 4.13) (Nikon Corporation,
Tokyo, Japan) and ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of
Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2018). The
DAVID (v6.8)70 database was used for GO functional annotation analysis.
Structure analysis was conducted with PyMOL (v2.2) (Schrödinger)71 and the
molecular modeling with Phyre2 (v2.0) (Structural Bioinformatics Group,
Imperial College, London)72. The combination indexes were determined with
the median dose-effect method (Chou and Talalay73) using CompuSyn soft-
ware (ComboSyn, Inc.). The TMA visualization was carried out with Aperio
ImageScope Pathology Slide Viewing Software (v12.3.3) (Leica Biosystems,
Nussloch, Germany). Network analysis and KEGG pathway mapping of
differentially regulated targets were performed by STRING (v11) (http://string-
db.org) and DAVID (v6.8) (https://david.ncifcrf.gov/) databases, respectively.
Lastly, GraphPad Prism (v8.4) was utilized for graphing and statistical analysis.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The RNA sequencing data have been deposited and are available in the Gene Expression
Omnibus (GEO) public database under accession numbers GSE92893 and GSE123740.
Source data are provided with this paper. The authors declare that all data supporting the
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